

**CURRICULUM VITAE**

**NAME:**        *Howard D. Homesley, M.D.*

	<b>PAGES</b>
<b>I.      PERSONAL PROFILE</b>	<b>2-18</b>
<b>II.     BIBLIOGRAPHY CITATIONS (317)</b>	
<b>IIA.   TEXTBOOK CHAPTERS (22)</b>	<b>19-22</b>
<b>IIB.   PEER REVIEW JOURNAL ARTICLES (190)</b>	<b>23-40</b>
<b>IIC.   ABSTRACTS (69)</b>	<b>41-47</b>
<b>IID.   NON-PEER REVIEW ARTICLES (36)</b>	<b>48-50</b>
<b>III.    PRESENTATIONS (162)</b>	<b>51-63</b>

**PERSONAL PROFILE:**

NAME:

Howard D. Homesley, M.D.

**ADDRESS:**

159 Dedham Loop  
 Mooresville, N.C 28117  
 Telephone: (704) 660-6451\  
 Cell: 252-917-0557  
 FAX: (704) 660-6451  
 email: [hdh7173@aol.com](mailto:hdh7173@aol.com)

**PERSONAL INFORMATION:**

BIRTHPLACE: Cherryville, North Carolina  
CITIZENSHIP: United States of America  
RELIGION: Protestant  
MARITAL STATUS: Married  
SPOUSE'S NAME: Jane Blackwelder  
BIRTHPLACE: Lincolnton, North Carolina  
CHILDREN: David (01-17-71) Orthopedic Surgeon, Charlotte, NC  
John (10-29-73), Film Editor, Hollywood, CA

**EDUCATION:**

1959 Cherryville, High School  
Cherryville, North Carolina  
  
1963 University of North Carolina  
Chapel Hill, North Carolina  
Bachelor of Arts - English  
  
1967 University of North Carolina School of Medicine  
Chapel Hill, North Carolina  
Doctor of Medicine

**POSTDOCTORAL TRAINING:**

1967-1968 Vanderbilt University Hospital  
Nashville, Tennessee  
Internship, Surgery  
1968-1971 Vanderbilt University Hospital  
Nashville, Tennessee  
Resident, Obstetrics & Gynecology  
1971-1973 Memorial Sloan-Kettering Cancer Center  
New York, New York  
Fellowship, Gynecologic Oncology

**UNIFORM SERVICE:**

BRANCH: United States Air Force

DATES SERVED: 1973-1975

COMMISSION: Major

**PROFESSIONAL LICENSURE:**

N.C. State License Number: 15495  
DEA Number: AH6407971  
UPIN Number: C84559  
Medicaid Number 3845756.  
National Provider Identifier 194292644  
NCI Number 7469

**SPECIALTY CERTIFICATION:**

1973 Diplomat, American Board of Obstetrics and Gynecology  
1976 Diplomat, American Board of Obstetrics and Gynecology:  
Subspecialty Certification in Gynecologic Oncology  
1993 Recertified, Diplomat, American Board of Obstetrics  
and Gynecology  
1996 Program for Continuing Professional Development Requirements  
Fulfilled, American College of Obstetrics and Gynecology  
2003 Recertified, Gynecologic Oncology, American Board of Obstetrics  
and Gynecology  
2006 Recertified, Gynecologic Oncology, American Board of Obstetrics  
and Gynecology

**EMPLOYMENT:**

1973-1975 Clinical Instructor and Clinical Assistant Professor  
University of California at Davis  
Department of Obstetrics and Gynecology  
1973-1975 Major, United States Air Force  
David Grant Medical Center  
Department of Obstetrics and Gynecology  
Chief Gynecologic Oncologist  
Travis Air Force Base, California  
1975-1978 Assistant Professor  
Wake Forest University School of Medicine  
Department of Obstetrics and Gynecology  
1978-1983 Associate Professor  
Wake Forest University School of Medicine  
Department of Obstetrics and Gynecology

1980-1996	Head, Section on Gynecologic Oncology Wake Forest University School of Medicine Department of Obstetrics and Gynecology
1983-1996	Professor Wake Forest University School of Medicine Department of Obstetrics and Gynecology
1996-Present	Professor Emeritus Wake Forest University School of Medicine Department of Obstetrics and Gynecology
1996-1999	Carolina Gynecologic Oncology/Brookview Women's Center
1999-2004	Gynecologic Oncology of Middle Tennessee
1999-2004	Clinical Professor Vanderbilt University School of Medicine Department of Obstetrics and Gynecology
2004-2009	Clinical Professor Brody School of Medicine Department of Obstetrics and Gynecology

**OTHER PROFESSIONAL APPOINTMENTS AND ACTIVITIES:**

1976-1991	Davie County Hospital (Consultant Staff) Mocksville, North Carolina
1975-1996	North Carolina Baptist Hospital Winston-Salem, North Carolina
1977-1999	Forsyth Medical Center Winston-Salem, North Carolina
1999-2004	Baptist Hospital (Active Staff) Nashville, Tennessee
1999-2004	Centennial Hospital (Consultant Staff) Nashville, Tennessee
1999-2004	St. Thomas Hospital (Consultant Staff) Nashville, Tennessee.
2004-2009	Pitt County Memorial Hospital (Active Staff) Greenville, North Carolina

**North Carolina Baptist Hospital:**

1975-1976	Utilization Review Committee
1975-1980	Operating Room Committee
1976-1980	Infection Control Committee
1976-1980	Cancer Committee
1983-1996	Chiefs of Professional Services
1990-1992	Laser Utilization and Safety Committee
1994-1996	Cancer Committee

**Wake Forest University School of Medicine**

1977-1980	Continuing Education and Lectureship Committee
1977-1980	Department of Clinics Committee
1977-1980	Frank R. Lock Symposium in Obstetrics and Gynecology, Program Chairman
1978-1979	Associate Director of Clinical Research Oncology Research Center
1983-1985	Cancer Support Volunteer Services Committee
1975-1988	Protocol Review and Development Committee
1985-1996	Clinical Faculty Advisory Committee
1990-1993	Clinical Oncology Steering Committee
1991-1992	Chairman, Subcommittee on Patient Advocacy
2010-Present	Scientific Integrity and Research Ethics Committee

**Forsyth Medical Center, Winston-Salem, NC**

1998-1999	Chart and Forms Committee
-----------	---------------------------

**Baptist Hospital, Nashville, TN**

2000-2004	Cancer Committee
2000-2001	Radiation Committee

**American Cancer Society:**

*Forsyth County Unit*

1976-1978	Professional Education Committee, Chairman
1978-1980	President
1980-1982	Chairman of the Board

*North Carolina Division*

1977-1979	Professional Education Committee
1977-1982	Board of Directors
1978-1979	Legacy Committee
1979-1982	Executive Committee
1979-1982	Special Projects Committee



**Gynecologic Oncology Group:**

1977-1978	Cervix, Vulva, Vagina Committee
1977-1979	Bylaws Committee
1978-1985	Membership Committee
1979-1981	Chairman, Bylaws Committee
1981-1984	Chairman, Quality Control Committee
1982-1983	Chairman, Cancer Control Committee
1982-1986	Executive Committee
1982-1986	Drug and Safety Monitoring Board
1982-1986	American College of Obstetrics and Gynecology Committee on Human Research
1987-1988	Gynecologic Oncologic Group/Southwest Oncology Group Intergroup Monitoring Committee
1977-2002	Corpus Committee
1984-1994	Chairman, Corpus Committee
1994-1998	Co-Chairman, Corpus Committee
1981-2000	Protocol Committee
1996-2000	Cancer Control Committee

**OTHER PROFESSIONAL APPOINTMENTS AND ACTIVITIES: (CONTINUED)**

Editorial Board:

1992-1999	GYNECOLOGIC ONCOLOGY
2008-Present	CLINICAL OVARIAN CANCER

***Ad Hoc Reviewer:***

1981-Present	OBSTETRICS AND GYNECOLOGY
1988-Present	CANCER
1988-Present	NEW ENGLAND JOURNAL OF MEDICINE
1990-Present	GYNECOLOGIC ONCOLOGY
1990-Present	AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY
1995-Present	JOURNAL OF PELVIC SURGERY
2002-Present	JOURNAL OF CLINICAL ONCOLOGY
2006-Present	ANNALS OF INTERNAL MEDICINE

***State of North Carolina:***

1983-1985	Obstetrical and Gynecological Liaison Advisory Committee
1990-1993	Cervical Cancer Task Force

**PROFESSIONAL INTERESTS:**

Clinical Investigation in All Aspects of Gynecologic Oncology

**GRANTS:**

- |    |           |   |
|----|-----------|---|
| 1. | 1977-2009 | National Cancer Institute<br>Gynecologic Oncology Group<br>Principal Investigator |
| 2. | 1980-1982 | Bristol Laboratories<br>Ceforanide Study<br>Principal Investigator                |
| 3. | 1980-1982 | A.H. Robins<br>Metaclopramide Study<br>Principal Investigator                     |
| 4. | 1981-1982 | Wyeth Laboratories<br>Ciramidol Study<br>Associate Investigator                   |
| 5. | 1981-1982 | Pfizer Incorporated<br>Levonantrodol Study<br>Principal Investigator              |



July 1, 2010

- |     |           |   |
|-----|-----------|---|
| 6.  | 1981-1982 | Lederle Laboratories<br>Piperacillin Study<br>Principal Investigator  |
| 7.  | 1982      | Schering Corporation<br>Interferon Study<br>Principal Investigator    |
| 8.  | 1982-1983 | Pfizer Incorporated<br>Sultamicillin Study<br>Principal Investigator  |
| 9.  | 1982-1983 | Hoechst-Roussel<br>Claforan Study<br>Associate Investigator           |
| 10. | 1983-1984 | Adria Labs<br>Indoprofen Study<br>Principal Investigator              |
| 11. | 1984-1985 | Schering Corporation<br>Interferon Study<br>Associate Investigator    |
| 12. | 1984-1986 | Adria Labs<br>Epirubicin Study<br>Principal Investigator              |
| 13. | 1984-1985 | Ortho Pharmaceutical<br>Terconazole Study<br>Principal Investigator   |
| 14. | 1985-1986 | A.H. Robins<br>Metaclopramide Study<br>Principal Investigator         |
| 15. | 1984-1987 | Purdue Frederick Company<br>MS Contin Study<br>Principal Investigator |
| 16. | 1986-1987 | Biogen<br>Intraperitoneal Gamma Interferon<br>Associate Investigator  |

- |     |           |  |
|-----|-----------|--|
| 17. | 1986-1987 | Schering<br>Intraperitoneal Gamma Interferon and Platinum<br>Associate Investigator    |
| 18. | 1987      | Ribi<br>Intraperitoneal Ovamid<br>Associate Investigator                               |
| 19. | 1987      | Ribi<br>Detox for Human Papilloma Virus<br>Associate Investigator                      |
| 20. | 1987-1988 | A.H. Robins<br>Zacopride<br>Principal Investigator                                     |
| 21. | 1987-1988 | Adria Labs<br>Toremifen Study<br>Principal Investigator                                |
| 22. | 1987-1990 | National Cancer Institute<br>Epidemiology Endometrial Cancer<br>Associate Investigator |
| 23. | 1987-1988 | Centocor<br>Imaging Studies<br>Principal Investigator                                  |
| 24. | 1988      | Dupont<br>Tumor Marker<br>Associate Investigator                                       |
| 25. | 1988-1989 | Purdue Frederick Company<br>Pain Studies<br>Principal Investigator                     |
| 26. | 1988-1989 | Ortho<br>HuEPO<br>Principal Investigator   |
| 27. | 1988-1990 | Merrill Dow Research Institute<br>MDL 72,222<br>Principal Investigator                 |

July 1, 2010

- |     |           |  |
|-----|-----------|--|
| 28. | 1989-1990 | Beecham Laboratories<br>BRL 436 94A<br>Principal Investigator              |
| 29. | 1989-1992 | Wyeth - Ayerst Labs<br>Premarin<br>Principal Investigator                  |
| 30. | 1989-1991 | Knoll Pharmaceuticals<br>Vicoprofen<br>Principal Investigator:             |
| 31. | 1990-1991 | Lilly<br>Gemcitabene<br>Principal Investigator                             |
| 32. | 1990-1992 | Merrill Dow Research Institute<br>DML 73, 147 EF<br>Principal Investigator |
| 33. | 1990-1992 | MGI<br>DDTC<br>Principal Investigator                                      |
| 34. | 1990-1992 | Organon<br>2766<br>Principal Investigator                                  |
| 35. | 1990-1993 | Amgen<br>Neupogen<br>Principal Investigator                                |
| 36. | 1992      | Rhone Poulence Rhorer<br>RG 12915<br>Principal Investigator                |
| 37. | 1992      | Janssen<br>Fentanyl Transdural System<br>Principal Investigator            |
| 38. | 1992-1993 | Serono<br>Interferon<br>Associate Investigator                             |

July 1, 2010

- |     |           |  |
|-----|-----------|--|
| 39. | 1992-1993 | Faulding Pharmaceutical<br>Kapanol<br>Principal Investigator       |
| 40. | 1992-1993 | Glaxo<br>Ondansetron<br>Principal Investigator                     |
| 41. | 1992-1994 | Purdue Frederick Co.<br>Analgesic Study<br>Associate Investigator  |
| 42. | 1991-1994 | Burroughs-Wellcome<br>Navelbine<br>Principal Investigator          |
| 43. | 1992-1994 | U.S. Biosciences<br>WR 2721<br>Principal Investigator              |
| 44. | 1993      | Ortho<br>Procrit<br>Principal Investigator                         |
| 45. | 1992-1994 | Marion Merrill Dow<br>Dolesetron<br>Principal Investigator         |
| 46. | 1993-1994 | Anthra<br>AD-32<br>Principal Investigator                          |
| 47. | 1994-1995 | SmithKline Beecham<br>Topotecan<br>Principal Investigator          |
| 48. | 1994-1995 | Glaxo<br>Oral Ondansetron<br>Principal Investigator                |
| 49. | 1994-1995 | SmithKline Beecham<br>Taxol vs Topotecan<br>Principal Investigator |

July 1, 2010

- |     |           |  |
|-----|-----------|--|
| 50. | 1995-1996 | Eli Lilly and Company<br>Raloxifene<br>Principal Investigator                |
| 51. | 1995-1996 | Immunex Corporation<br>Mitoxantrone<br>Associate Investigator                |
| 52. | 1995-1996 | Baker Norton Pharmaceuticals, Inc.<br>Paclitaxel<br>Principal Investigator   |
| 53. | 1995-1996 | Glaxo<br>Ondansetron<br>Principal Investigator                               |
| 54. | 1995-1996 | Anesta<br>Transcutaneous Fentanyl<br>Principal Investigator                  |
| 55. | 1996-1999 | Wyeth-Ayerst<br>Low Dose Estrogen<br>Principal Investigator                  |
| 56. | 1996-1999 | Alza<br>Amifostene and Intraperitoneal Therapy<br>Principal Investigator     |
| 57. | 1996-1999 | Anthra<br>AD 32 vs Hexelen<br>Principal Investigator                         |
| 58. | 1996-1998 | Baker Norton<br>96 Hour Infusion of Ovarian Cancer<br>Principal Investigator |
| 59. | 1996-1998 | Glaxo<br>Opioid Antiemetic<br>Principal Investigator                         |
| 60. | 1996-1998 | Ligand<br>Targretin for Ovarian Cancer<br>Principal Investigator             |

July 1, 2010

- |     |           |  |
|-----|-----------|--|
| 61. | 1996-1998 | Matrix<br>Injectable Cisplatin<br>Principal Investigator     |
| 62. | 1996-1998 | Boehringer Ingelheim<br>Itasetron<br>Principal Investigator  |
| 63. | 1996-1998 | Zeneca<br>Kadian<br>Principal Investigator                   |
| 64. | 1997-1999 | SmithKline Beecham<br>Topotecan<br>Principal Investigator    |
| 65. | 1998-2004 | Bristol-Myers Squibb<br>Paclitaxel<br>Principal Investigator |
| 66. | 1998-1999 | Sequus<br>Doxil vs Topotecan<br>Principal Investigator       |
| 67. | 1998-1999 | Parke-Davis<br>DENSA<br>Principal Investigator               |
| 68. | 1998-1999 | Knoll<br>Vicoprofen<br>Principal Investigator                |
| 69. | 1998-1999 | Lilly<br>SERM<br>Principal Investigator                      |
| 70. | 1999-1999 | Schering-Plough<br>SCH58500<br>Principal Investigator        |
| 71. | 1997-1999 | Bristol<br>Paclitaxel<br>Principal Investigator              |

July 1, 2010

72.	1999-1999	Zenaca ZD 9331 Principal Investigator
73.	1999-2001	SmithKlineBeecham Topotecan Principal Investigator
74.	2001-2002	Daiichi Exetecan Principal Investigator
75.	2001-2003	Impath Tumor Procurement Principal Investigator
76.	2003	Amgen Darbepoetin alpha Principal Investigator
77.	2003-2004	Lilly Gemcitabene Principal Investigator
78.	2003-2004	Nuvelo Alfimeprase Principal Investigator
79.	2004	Amgen Neulasta Principal Investigator
80.	2004-2005	CARE Test Cancer Research Center of West Tennessee Principal Investigator
81.	2003-2004	Unither OvaRex Principal Investigator
82.	2002-2004	Horizon Medical Products Vortex Port Principal Investigator

July 1, 2010

83.	2004	Amgen Darbepoetin alpha Principal Investigator
84.	2005-2009	Johnson and Johnson Yondelis Principal Investigator
85.	2005-2007	Keryx Perifosine Principal Investigator
86.	2005-2006	Helsinn Palonosetron Principal Investigator
87.	2005-2006	Cephalon Fentanyl Principal Investigator
88.	2005-2009	Tripath Oncology Serum Collection Principal Investigator
89.	2005-2009	Lilly Gemcitabine Principal Investigator
90.	2006-2009	Sanofi Aventis VEGF Trap Principal Investigator
91.	2007-2009	PTI Registry Study Principal Investigator
92.	2007-2009	DiaTech Trial Principal Investigator
93.	2007-2009	Novartis Patupilone Principal Investigator
94.	2007-2008	Bayer ZK-Epothilone Principal Investigator



July 1, 2010

95. 2007-2009 Genentech  
Bevacizumab Trial  
Principal Investigator

**PROFESSIONAL MEMBERSHIPS:**

1. 1973-Present American College of Obstetricians and Gynecologists
2. 1975-1999 Forsyth-Stokes-Davie County Medical Society
  - 1988-1991 Chairman, Legislative Committee
  - 1988-1995 Executive Committee
  - 1990-1991 Alternate Delegate to NC Medical Society
  - 1990-1991 Treasurer
  - 1991 Secretary
  - 1992 President-Elect
  - 1992-1994 Delegate to NC Medical Society
  - 1993-1994 President
  - 1994-1995 Past-President
3. 1975-1999 North Carolina Medical Society
  - 1976-1983 Committee On Cancer
  - 1987-1988 Advisory Panel on Obstetrics and Gynecology
  - 1991-1999 Cancer Committee
  - 1991-1992 Chairman, Subcommittee on Reimbursement
  - 1991-1994 MEDPAC Committee
  - 1992-1994 Nominating Committee
  - 1993-1994 Chairman
  - 1993-1994 Executive Council
4. 1977-1990 Memorial Alumni Society
5. 1977-2004 American Society for Colposcopy and Clinical Pathology
  - 1982-1985 Bylaws Committee
6. 1977-Present American Society of Clinical Oncologists
7. 1977-1999 North Carolina Obstetrical and Gynecologic Society
  - 1980-1983 Executive Committee
  - 1980-1983 Program Chairman
  - 1980-1983 Executive Committee
  - 1986-1990 President-Elect
  - 1986-1987 President
  - 1987-1988 Immediate Past President
  - 1989-1990 Past President
  - 1988-1991 GOPAC Committee
  - 1988-1991 Legislative Committee
  - 1989-1992 Chairman, Professional Affairs Council
8. 1978-Present Society of Surgical Oncologists
9. 1978-Present American College of Surgeons
  - 1988-1991 Executive Committee of NC Chapter
10. 1978-Present Society of Gynecologic Oncologists
  - 1985-1993 Nomenclature and Staging Committee

July 1, 2010

- |           |   |
|-----------|---|
| 1990-1991 | Chair, Nomenclature and Staging Committee |
| 1990-1991 | Program Committee                         |
| 1991-1994 | Council Member                            |
| 1992-1994 | Communications & Government Relations     |
| 1994-1999 | Chairman, Education and Development       |
| 1995-1996 | Vice-President                            |
| 1998-1999 | Education Committee                       |
11. 1978-Present Society of Memorial Gynecologic Oncologists
 

1979-1981	Executive Board
1979-1981	President
1981-1983	Nominating Committee
1989-1990	Program Committee
  12. 1979-1985 Gynecologic Urology Society
  13. 1979-1994 Gynecologic Laser Society
  14. 1981-1999 American Medical Association
  15. 1982-1999 South Atlantic Association of Obstetricians and Gynecologists
  16. 1984-2000 American Radium Society
  17. 1976-Present Frank Lock Society
  18. 1986-Present International Gynecologic Cancer Society
 

1986-1987	Steering Committee
1995-1997	Program Committee
  19. 1987-1999 Mid Atlantic Gynecologic Oncologic Society
  20. 1990-1993 American Institute of Ultrasound in Medicine
  21. 1990-2004 European Society of Gynecologic Oncology
  22. 1991-1999 Winston-Salem Surgical Society
  23. 1991-Present American Gynecological and Obstetrical Society
  24. 1991-Present Society of Pelvic Surgeons
  25. 1993-1999 The American Association of Gynecologic Laparoscopists
  26. 2000-2003 Federation of Physicians and Dentists
  27. 1999-2004 Tennessee Medical Association
  28. 1999-2004 Nashville Academy of Medicine
  29. 1999-2004 Obstetrical and Gynecological Society of Nashville

HONORS AND AWARDS:

1963	University of North Carolina -Phi Beta Kappa
1975-1978	American Cancer Society- Junior Clinical Faculty Fellowship
1993	The Best Doctors in America (First Edition)
1994	The Best Doctors in America (Second Edition)
1996	The Best Doctors in America: Southeast Region (First Edition)
1998	The Best Doctors in America (Fourth Edition)
1999	Life Member (#72596) National Registry of Who's Who
2001	The Best Doctors in America
2002	The Best Doctors in America
2003	The Best Doctors in America
2004	The Best Doctors in America
2005	The Best Doctors in America
2006	The Best Doctors in America
2007	The Best Doctors in America
2008	The Best Doctors in America
2009	The Best Doctors in America

**BIBLIOGRAPHY:**

**IIA. TEXT BOOK CHAPTERS:**

1. Homesley HD, Lewis JL. Treatment of endometrial adenocarcinoma at Memorial Hospital New York 1984-1976. In: Gray LA, ed. Endometrial carcinoma and its treatment: the role irradiation, extent of surgery, and approach to chemotherapy. Springfield, Ill: Charles C. Thomas, 1977:99-177.
2. Thigpen T, Shingleton H, Homesley HD, DiSaia P, Lagasse L, Blessing J. Cis-diaminedichloro-platinum (II) in the treatment of advanced or recurrent Cervix and uterine cancer: Phase II trials of the gynecologic oncology group - Cisplatin: current status and new developments. Prestayko AW, Crooke ST, Carter SK, Eds. New York: Academic Press, 1980:411-422.
3. Homesley HD. The appropriate extent of bulk resection in advanced ovarian cancer. In: Ballon S, Ed. Gynecology oncology: controversies in cancer treatment, Boston: G.K. Hall, 1981:321-331.
4. Homesley HD. Cancer of the female genital tract. In: Atwell BM, Michielutte R, Eds. Cancer patient support manual. Winston-Salem, NC: Oncology Research Center, Bowman Gray School of Medicine, North Carolina Baptist Hospital, 1982:41-52.
5. Welanders CE, Morgan TM, Homesley HD. Multiple factors predicting responses to combination chemotherapy in patients with ovarian cancers. In: Salmon SE, Trent JM, Eds. Human Tumor cloning. New York: Grune & Stratton, 1984:521-534.
6. Homesley HD. Carcinoma of the vulva. In: Rakel RE, Ed. Conn's current therapy. Philadelphia: Saunders, 1985:899-903.
7. Homesley HD. Carcinoma of the vulva. In: Rakel RE, Ed. Conn's Current Therapy. Philadelphia: Saunders, 1986:888-894.
8. Homesley HD. Carcinoma of the vulva. In: Rakel RE, Ed. Conn's Current Therapy. Philadelphia: Saunders, 1987:914-918.
9. Homesley HD. Postmenopausal bleeding in a diabetic woman. In: Wanebo, Ed. Common problems in surgical oncology. Chicago: Year Book Medical Publishers, 1989; VII: 285-289.
10. Homesley HD, Sevin BU. Treatment of vulvar cancer - the GOG experience. In: Knapstein et al, Eds. Malignancies of the vulva.

11. Homesley HD. The revised (1988) FIGO staging systems for endometrial and vulvar cancer: an assessment. In: Podratz K, Ed. New diagnostic techniques in gynecology. Philadelphia: J.P. Lippincott 1992:89-94.
12. Homesley HD. Revised 1988 International Federation of Gynecology and Obstetrics Staging Systems for Endometrial and Vulvar Cancer; An Assessment. In: Podratz KC. Clin Obstet Gynec., Hagerstown: J.B. Lippincott, Co. 1992; 35:89-94.
13. Homesley HD. Endometrial carcinoma: preoperative evaluation, surgical staging, lymph node sampling, and surgical treatment. In: Sugarbaker PH. Pelvic Surgery for Cancer: An Interdisciplinary Approach. B.C. Decker Company. 1994; 205-216.
14. Homesley HD. Geriatric Gynecology. In: Hazzard WR, et al, Eds. Principles of Geriatric Medicine and Gerontology. 3<sup>rd</sup> edition. New York: McGraw-Hill. 1994; 473-480.
15. Homesley HD. Vulvar Cancer. IN: David S. Fisher. Follow-up of Cancer. A Handbook for Physicians.” 4<sup>th</sup> edition. Philadelphia: Lippincott-Raven. 1995; 90-91.
16. Homesley HD. Chemotherapy of Nonmetastatic Gestational Trophoblastic Disease. In: Hancock B, Ed. Gestational Trophoblastic Disease. London, UK: Chapman and Hall. 1997; 191-197.
17. Lentz SS, Homesley HD. Gynecologic Problems in Elderly Women. In: Beck L. Clinics in Geriatric Medicine, Philadelphia: W.B. Saunders Company. 1998; 14(2) 297-315.
18. Homesley HD. Historical Overview of Surgical Treatment for Cervical Cancer in the U.S.A. In: Yajima A & Kuwabara Y., Eds. Radical Surgery for Cancer of the Cervix Tokyo: Medical View. 1998.
19. Homesley HD. Vulvar Cancer. In: Visscher HC, Precis J. Washington, DC, American College of Obstetrics and Gynecology, 1998.
20. HOMESLEY HD. TREATMENT OF NON-METASTATIC GESTATIONAL TROPHOBLASTIC DISEASE. In: Hancock B, Ed. Gestational Trophoblastic Disease. 2<sup>nd</sup> Edition London, UK: Chapman and Hall. 2003; 293-304.
21. HOMESLEY HD AND MANNETA A. CANCER OF THE UTERINE CORPUS, IN MANNETA, A. EDS. CANCER PREVENTION AND EARLY DIAGNOSIS IN WOMEN. PHILADELPHIA, PA. MOSBY. 2003; 267-288.

22. HOMESLEY, HD COMBINED THERAPY IN. LUESLEY D, LAWTON F,  
AND BERCHUCK, A EDS. UTERINE CANCER. NEW YORK, NY MARCEL  
DEKKER, INC, 2006, 281-289

## **IIB. PEER REVIEW JOURNAL ARTICLES**

1. Homesley HD, Goss DA. Menstrual dysfunction following use of oral contraceptives. *Obstet Gynecol* 1970; 35:734-739.
2. Homesley HD, Zelenik JS. Hazards of central venous pressure monitoring: pericardial tamponade. *Am J Obstet Gynecol* 1971; 109:1216-1217.
3. Homesley HD, Zelenik JS. Is there a "best time" for postpartum vaginal hysterectomy? *Am J Obstet Gynecol* 1972; 112:972-977.
4. Hilaris BS, Ju HW, Lewis JL JR, Homesley HD, Kim JH. Normal and neoplastic tissue effects of high intensity intracavitary irradiation: cancer of the corpus uteri. *Radiology* 1974; 110:459-462.
5. Homesley HD, Boronow RC, Lewis JL JR. Treatment of adenocarcinoma of the endometrium at Memorial-James Ewing Hospitals, 1949-1965. *Obstet Gynecol* 1976; 47:100-105.
6. Chang SH, Roberts JM, Homesley HD. Proliferating Brenner tumor. *Obstet Gynecol* 1977; 49:489-493.
7. Haid M, Homesley HD, White DR, Cooper MR, Richards F II, Muss HB, Spurr CL. Adriamycin methotrexate combination chemotherapy of advanced carcinoma of the cervix: a second look. *Obstet Gynecol* 1977; 50:103-105.
8. Homesley HD, Boronow RC, Lewis JL JR. Stage II endometrial adenocarcinoma: Memorial Hospital for cancer, 1949-1965. *Obstet Gynecol* 1977; 49:604-608.
9. Morrison LM, Homesley HD. Carcinoma of the cervix complicated by a soup spoon. *Obstet Gynecol* 1978; 51:5s-6s.
10. Galle PC, Muss HB, McGrath KM, Stuart JJ, Homesley HD. Thrombocytopenia and bleeding in two patients treated with low-dose heparin. *Obstet Gynecol* 1978; 52(Suppl): 9s-11s.
11. Roberts JM, Homesley HD. Low-dose carbenicillin prophylaxis for vaginal and abdominal hysterectomy. *Obstet Gynecol* 1978; 52:83-87.
12. Galle PC, Homesley HD, Rhyne AL. Reassessment of the surgical scrub. *Surg Gynecol Obstet* 1978; 147:215-218.
13. Roberts JM, Homesley HD. Observations on bladder function following radical hysterectomy using carbon dioxide cystometry. *Surg Gynecol Obstet* 1978; 147:558-560.

14. Heise ER, Kucera LS, Raben M, Homesley HD. Serological response patterns to herpes virus type 2 early and late antigens in cervical carcinoma patients. *Cancer Res* 1979; 39:4022-4026.
15. Brady LW, Blessing JA, Slayton RE, Homesley HD, Lewis GC. Radiotherapy (RT), chemotherapy (CT), and combined therapy in stage III epithelial ovarian cancer. *Cancer Clin Trials* 1979; 2:111-120.
16. Thigpen T, Shingleton H, Homesley HD, LaGasse L, Blessing J. cis-Dichlorodiammineplatinum (II) in the treatment of gynecologic malignancies: phase II trials by the Gynecologic Oncology Group. *Cancer Treat Rep* 1979; 63:1549-1555.
17. Galle PC, Homesley HD. Lethal peritonitis following internal small bowel herniation and infarction after use of a simplified stapler colostomy technique. *Gynecol Oncol* 1980; 9:117-119.
18. Homesley HD, Raben M, Blake DD, Ferree CB, Bullock MS, Linton EB, Greiss FC, Rhyne AL. Relationship of lesion size to survival in patients with stage 1B squamous cell carcinoma of the cervix uteri treated by radiation therapy. *Surg Gynecol Obstet* 1980; 150:529-531.
19. Taylor DD, Homesley HD, Doellgast GJ. Binding of specific peroxidase-labeled antibody to placental-type phosphatase on tumor-derived membrane fragments. *Cancer Res* 1980; 40:4064-4069.
20. Galle PC, Homesley HD. Ineffectiveness of povidone-iodine irrigation of abdominal incisions. *Obstet Gynecol* 1980; 55:744-747.
21. Galle PC, Jobson VW, Homesley HD. Umbilical metastasis from gynecologic malignancies: a primary carcinoma of the fallopian tube. *Obstet Gynecol* 1981; 57:531-533.
22. Payne D, Muss HB, Homesley HD, Jobson VW, Baird FG. Autoimmune hemolytic anemia and ovarian dermoid cysts: case report and review of the literature. *Cancer* 1981; 48:721-724.
23. Thigpen T, Shingleton H, Homesley HD, LaGasse L, Blessing J. Cis-platinum in treatment of advanced or recurrent squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group. *Cancer* 1981; 48:899-903.
24. Gusdon JP, Homesley HD, Muss HB, Heise ER, Herbst GA, Richards F, Spurr CL, Lovelace JV, DiSaia PJ. Chemotherapy of advanced ovarian epithelial carcinoma with melphalan and levamisole: a pilot study of the Gynecologic Oncology Group. *Am J Obstet Gynecol* 1981; 141:65- 70.



25. Galle PC, Urban RB, Homesley HD, Jobson VW, Wheeler AS. Single dose carbenicillin versus T-tube drainage in patients undergoing vaginal hysterectomy. *Surg Gynecol Obstet* 1981; 153: 351-352.
26. Jackson DV JR, Sethi VS, Spurr CL, Willard V, White DR, Richards F II, Stuart JJ, Muss HB, Cooper MR, Homesley HD, Jobson VW, Castle MC. Intravenous vincristine infusion: phase I trial. *Cancer* 1981; 48:2559-2564.
27. Pippitt CH, Muss HB, Homesley HD, Jobson VW. Cisplatin-associated cortical blindness. *Gynecol Oncol* 1981; 12:253-255.
28. Arseneau JC, Bundy B, Dolan T, Homesley HD, DiSaia PJ. Phase II study of Baker's antifol (triazinate, TZT, NCS-139, 105) in advanced squamous cell carcinoma of cervix. *Am J Clin Oncol* 1982; 5:61-64.
29. Nelson LH, Fry RJ, Homesley HD, Semmer JR. Malignant ovarian tumors simulating hydatiform mole on ultrasound. *JCU* 1982; 10:249-251.
30. Omura GA, Morrow CP, Blessing JA, Miller A, Buchsbaum HJ, Homesley HD, Leone L.A. Randomized comparison of melphalan versus melphalan plus hexamethylmelamine vs adriamycin plus cyclophosphamide in ovarian carcinoma. *Cancer* 1983; 51:783-789.
31. Taylor DD, Homesley HD, Doellgast GJ. "Membrane-associated" immunoglobulins in cyst and ascites fluids of ovarian cancer patients. *Am J Reprod Immunol* 1983; 3:7-11.
32. Thigpen JT, LaGasse L, Homesley H, Blessing JA. Cis-platinum in the treatment of advanced or recurrent adenocarcinoma of the ovary: a phase II study of the Gynecologic Oncology Group. *Am J Clin Oncol* 1983; 6:431-435.
33. Thigpen JT, Blessing JA, Homesley HD, Adcock LL. Phase II trial of piperazinedione (NCS-135758) in the treatment of advanced or recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. *Am J Clin Oncol* 1983; 6:423-426.
34. Arseneau JC, Bundy B, Homesley HD, Beecham J. Phase II study of Baker's antifol (triazinate, TZT, NSC 139, 105) in advanced carcinoma of the ovary: a Gynecologic Oncology Group study. *Invest New Drugs* 1983; 1:185-188.
35. Bonomi P, Blessing JA, Sedlacek TV, Homesley HD, DiSaia PJ. Phase II trial of AMSA in patients with advanced or recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. *Cancer Treat Rep* 1983; 67:197-198.

36. Welanders CE, Homesley HD, Jobson VW. In vitro chemotherapy testing of gynecologic tumors: basis for planning therapy? *Am J Obstet Gynecol* 1983; 147:188-195.
37. Jobson VW, Homesley HD. Treatment of vaginal intraepithelial neoplasia with the carbon dioxide laser. *Obstet Gynecol* 1983; 62:90-93.
38. Gusdson JP, Homesley HD, Jobson VW, Muss HB. Treatment of advanced ovarian malignancy with chemoimmunotherapy using autologous tumor and *Corynebacterium parvum*. *Obstet Gynecol* 1983; 62:728-735.
39. Doellgast GJ, Homesley HD. Placental-type alkaline phosphatase in ovarian cancer fluids and tissues. *Obstet Gynecol* 1984; 63:324-329.
40. Cohen CJ, Bruckner HW, Deppe G, Blessing JA, Homesley HD, Lee JH, Watring W. Multi-drug treatment of advanced and recurrent endometrial carcinoma: a Gynecologic Oncology Group study. *Obstet Gynecol* 1984;63:719-726.
41. Slavik M, Petty WM, Blessing JA, Creasman WT, Homesley HD. Phase II clinical study of tamoxifen in advanced endometrial adenocarcinoma: a Gynecologic Oncology study. *Cancer Treat Rep* 1984; 68:809-811.
42. Thigpen JT, Blessing JA, LaGasse LD, DiSaia PJ, Homesley HD. A phase II trial of cisplatin as second-line chemotherapy in patients with advanced or recurrent endometrial carcinoma: Gynecologic Oncology Group study. *Am J Clin Oncol* 1984; 7:253-256.
43. Thigpen JT, Blessing JA, Arseneau JC, Homesley HD. Phase II trial of piperazinedione (NSC 135758) in the treatment of advanced or recurrent carcinoma of the ovary: Gynecologic Oncology Group Study. *Am J Clin Oncol* 1984; 7; 261-263.
44. Stehman FB, Blessing JA, Homesley HD, Currie JL, Yordan EL. Phase II evaluation of dianhydrogalactitol in the treatment of advanced non-squamous cervical carcinoma: Gynecologic Oncology Group study. *Invest New Drugs* 1984; 2:331-333.
45. Taylor DD, Homesley HD, Doellgast GH. Identification of antigenic components recognized by "membrane-bound" antibodies from ovarian cancer patients. *Am J Reprod Immunol* 1984; 6:179-184.
46. Parker RL Jr, Welanders CE, Homesley HD, Jobson VW, Kawamoto EH. Use of the human tumor stem cell assay to study chemotherapy sensitivity in cancer of the cervix. *Obstet Gynecol* 1984; 64:412-416.

47. Slayton RE, Blessing JA, Homesley HD. Phase II Trial of etoposide in the management of advanced or recurrent non-squamous cell carcinoma of the cervix: (a Gynecologic Oncology Group study). *Cancer Treat Rep* 1984; 68:12.
48. Homesley HD, Jobson VW, Reish RL. Use of colposcopically directed, four-quadrant cervical biopsy by the colposcopy trainee. *J Reprod Med* 1984; 29:311-316.
49. Littleton RE, Homesley HD, Richards F II. Leukemogenesis related to chemotherapy of ovarian carcinoma: review with three new case reports. *Gynecol Oncol* 1984; 19:268-277.
50. Jobson VW, Homesley HD. Comparison of cryosurgery and carbon dioxide laser ablation for treatment of cervical intraepithelial neoplasia. *Colposcopy Gynecol Laser Surg* 1984; 1:173-180.
51. Jobson VW, Muss HB, Thigpen JT, Homesley HD, Bundy B. Chemotherapy of advanced squamous carcinoma of the cervix: a phase I-II study of high-dose cisplatin and cyclophosphamide: a pilot study of the Gynecologic Oncology Group. *Am J Clin Oncol*. 1984; 7:341-345.
52. Welander CE, Morgan TM, Homesley HD, Trotta PP, Spiegel RJ. Combined recombinant human interferon alpha<sub>2</sub> and cytotoxic agents studies in a clonogenic assay. *Int J Cancer* 1985; 35:721-729.
53. Muss HB, Bundy B, DiSaia PJ, Homesley HD, Fowler WC Jr, Creasman W, Yordan E. Treatment of recurrent or advanced uterine sarcoma: a randomized trial of doxorubicin versus doxorubicin and cyclophosphamide (a phase III trial of the Gynecologic Oncology Group). *Cancer* 1985; 55:1648-1653.
54. Muss HB, Capizzi RL, Atkins JN, Powell BL, Cooper MR, Ferree D, McMahan RA, Jobson VW, Craig J, Homesley HD, Jackson DV JR, Richards F II, Spurr CL, Stuart JJ, White DR, Cruz JM, Zekan PJ. Phase I trials of high-dose cytosine arabinoside (HD ara-C) and HD ARA-C plus cisplatin in patients with advanced malignancies. *Semin Oncol* 1985; 12(2 suppl 3):166-170.
55. Jones CM III, Homesley HD. Successful treatment of pseudomyxoma peritonei of ovarian origin with cis-platinum, doxorubicin, and cyclophosphamide. *Gynecol Oncol* 1985; 22:257-259.
56. Muss HB, Homesley HD, Ruddick SA, Plunkett S, Caponera M., Cooper MA, Jackson DV, Jobson VW, Richards F III, Spurr CL, Stuart JJ, Welander C, White DA, Ferraresi RL, Norrel S. A phase I trial of recombinant leukocyte  $\gamma$ 2 interferon in patients with advanced malignancy. *Am J Clin Oncol* 1985; 8:97-107.

57. Kitten WH, Welander CE, Homesley HD, Doellgast GJ. Autologous antibodies eluted from membrane fragments isolated from the effusions of human ovarian epithelial neoplasms. I. Quantitation of antibodies. *Am J Obstet Gynecol* 1985; 153:124-129.
58. Muss HB, Capizzi RL, Atkins JN, Powell BL, Cooper MR, Ferree D, McMahan RA, Jobson V, Craig J, Homesley HD, Jackson DV JR, Richards F II Spurr CL, Stuart JJ, White DR, Cruz JM, Zekan PJ. Phase I trials of high-dose cytosine arabinoside (HD ARA-C) and HD ARA-C plus cisplatin in patients with advanced malignancies. *Semin Oncol* 1985; 12(2 suppl):166-170.
59. Welander CE, Morgan TM, Homesley HD, Trotta PP, Spiegel RJ. Combined recombinant human interferon alpha<sub>6</sub> and cytotoxic agents studied in a clonogenic assay. *Int J Cancer* 1985; 35:721-729.
60. Homesley HD, Wolff JL, Reish RL, Jobson VW. Evaluating the acquisition of colposcopy skills in an obstetric-gynecologic residency program. *J Reprod Med* 1985; 30:911-914.
61. Thigpen JT, Blessing J, Homesley HD, Hacker N, Curry SL. Phase II trial of piperazinedione in patients with advanced or recurrent uterine sarcoma: a Gynecologic Oncology Group study. *Am J Clin Oncol* 1985; 8:350-352.
62. Homesley HD, Blessing J, Conroy J, Hatch K, DiSaia PJ, Twiggs LB. ICRF-159 (razoxane) in patients with advanced adenocarcinoma of the endometrium: a Gynecologic Oncology Group study. *Am J Clin Onc* 1986; 9:15-17.
63. Thigpen JT, Blessing J, Homesley HD, Berek JS, Creasman WT. Phase II trial of cisplatin in advanced or recurrent cancer of the vagina: a Gynecologic Oncology Group study. *Gynecol Oncol* 1986; 23(1):101-4.
64. Thigpen JT, Blessing J, Homesley HD, Lewis GC JR. Phase II trials of cisplatin and piperazinedione in advanced or recurrent squamous cell carcinoma of the vulva: a Gynecologic Oncology Group study. *Gynecol Oncol* 1986; 23(3):358-63.
65. Morrow CP, Bundy B, Hoffman J, Sutton G, Homesley HD. Adriamycin chemotherapy for malignant mixed mesodermal tumor of the ovary: A Gynecologic Oncology Group study. *Am J Clin Oncol* 1986; 9(1):24-26.
66. Thigpen JT, Blessing J, Homesley HD, Lewis GC JR. Phase II trial of piperazinedione in the treatment of advanced or recurrent endometrial carcinoma: A Gynecologic Oncology Group study. *Am J Clin Oncol* 1986; 9; 21-23.
67. Slayton RE, Blessing J, Sutton G, Homesley HD, Park R. A Phase II clinical trial of Diazi-quone (AZQ) in the treatment of patients with epithelial ovarian cancer: A Gynecologic Oncology study. *Cancer Treat Rep* 1986; 70:309-310.

68. Gall S, Bundy B, Beecham J, Whitney C, Homesley HD, Lifshitz S, Adcock LL. Therapy of stage III (optimal) epithelial carcinoma of the ovary with melphalan plus corynebacterium parvum: a Gynecologic Oncology Group study. *Gynecol Oncol* 1986; 25:26-36.
69. Jackson DV JR, Jobson V, Homesley HD, Welander C, Hire E, Richards F II, Muss HB. Vincristine infusion in refractory gynecologic malignancies. *Gynecol Oncol* 1986; 25:212-216.
70. Geisinger KR, Homesley HD, Morgan TM, Kute TE, Marshall RB. Endometrial adenocarcinoma. A multi-parameter clinicopathologic analysis including DNA profile and the sex steroid hormone receptors. *Cancer* 1986; 58(7):1518-25.
71. Geisinger KR, Kute TE, Marshall RB, Homesley HD, Morgan TM. Analysis of the relationship of the ploidy and cell cycle kinetics to differentiation and the female sex steroid hormone receptors in adenocarcinoma of the endometrium. *Am J Clin Pathol* 1986; 85:536-541.
72. Homesley HD, Blessing JA, Berman M. ICR7-159 (razoxane) in patients with advanced nonsquamous cell carcinoma of the cervix: A Gynecologic Oncology Group study. *Am J Clin Oncol* 1986; 325-326.
73. Geisinger KR, Marshall RB, Kute TE, Homesley HD. Correlation of female sex steroid hormone receptors with histologic and ultrastructure differentiation in adenocarcinoma of the endometrium. *Cancer* 1986; 58(7):1506-17.
74. Herman JM, Homesley HD, Dignan MB. Is hysterectomy a risk factor for vaginal cancer? *JAMA* 1986; 256:601-603.
75. Homesley HD, Welander CE, Muss HB, Richards F. Dosage range study of morphine sulfate controlled-release. *Am J Clin Oncol* 1986; 9:449-453.
76. Homesley HD, Bundy BN, Sedlis A, Adcock L. Radiation therapy versus pelvic node resection for carcinoma of the vulva with positive groin nodes. *Obstet Gynecol* 1986; 68:733-740.
77. Omura G, Blessing J, Ehrlich CE, Miller A, Yordan E, Creasman WT, Homesley HD. A randomized trial of cyclophosphamide and doxorubicin with or without cisplatin in advanced ovarian carcinoma: A Gynecologic Oncology Group study. *Cancer* 1986; 57:1725-1730.
78. Sevin B-U, Homesley HD. Das Vulvakarzinom. *Gynäkologe* 1986; 19:109-115.
79. Muss HB, Jobson VW, Homesley HD, Welander C, Ferree C. Neoadjuvant therapy for advanced squamous cell carcinoma of the cervix: cisplatin followed

by radiation therapy - a pilot study of the Gynecologic Oncology Group. *Gynecol Oncol* 1987; 26(1):35-40.

80. Sedlis A, Homesley HD, Bundy B, Marshall R, Yordan E, Hacker N, Lee JH, Whitney C. Positive groin lymph nodes in superficial squamous cell vulvar cancer: A Gynecologic Oncology Group study. *Am J Obstet Gynecol* 1987; 156:1159-1164.
81. Jones CM, Welandar CE, Berens ME, Homesley HD. In vitro growth characteristics and chemosensitivities of endometrial cancer using a soft agar clonogenic assay. *Obstet Gynecol* 1987; 69(2):237-241.
82. Roberts JA, Blessing J, McGehee R, Beecham J, Homesley HD. Phase II trial of Dichloromethotrexate in patients with advanced squamous cell carcinoma of the cervix: A Gynecology Oncology Group Study. *Cancer Treat Reports* 1987; 71:1295-1296.
83. Muss HB, Bundy BN, Homesley HD, Wilbanks G. Mitoxantrone in the treatment of advanced non-squamous carcinoma of the cervix (a phase II trial of the Gynecologic Oncology Group). *Invest New Drugs* 1987; 5:199-202.
84. Asbury RF, Blessing J, Mortel R, Homesley HD, Malfetano J. Aminothiadiazone (NSC #4728) in patients with advanced cervical carcinoma: A phase II study of the Gynecologic Oncology Group. *Am J Clin Oncol* 1987; 10:299-301.
85. Creasman WT, Morrow CP, Bundy BN, Homesley HD, Graham J, Heller PB. Surgical pathologic spread patterns of endometrial cancer: A Gynecologic Oncology Group study. *Cancer* 1987; 60:2035-2041.
86. Roberts JA, Blessing J, McGehee R, Beecham J, Homesley HD. Phase II trial of dichloromethotrexate in patients with advanced squamous cell carcinoma of the cervix: A Gynecologic Oncology Group study. *Cancer Treat Rep* 1987; 71:1295-1296.
87. Creasman WT, Morrow CP, Bundy B, Homesley HD, Graham JE, Heller PB. Surgical pathologic spread patterns of endometrial cancer: A Gynecologic Oncology Group study. *Cancer* 1987; 60:2035-2041.
88. Muss HB, Bundy B, Homesley HD, Wilbanks G. Mitoxantrone in the treatment of advanced non-squamous carcinoma of the cervix (a phase II trial of the Gynecologic Oncology Group). *Invest New Drugs* 1987; 5:199-202.
89. Thigpen JF, Blessing JA, Ball H, Hanjani P, Manetta A, Homesley HD. Hexamethylmelamine as first-line chemotherapy in the treatment of advanced or recurrent carcinoma of the endometrium: A Phase II trial of the Gynecologic Oncology Group. *Gynecol Oncol* 1988; 31(3):435-438.

90. Welander CE, Homesley HD, Reich SD, Levin EA. A Phase II study of the efficacy of recombinant interferon gamma in relapsing ovarian adenocarcinoma. *Am J Clin Oncol* 1988; 11:465-469.
91. Homesley HD, Blessing J, Rettenmaier M, Capizzi RL, Major FJ, Twigg LB. Weekly intramuscular methotrexate for nonmetastatic gestational trophoblastic disease. *Obstet Gynecol* 1988; 72(3 pt 1):413-418.
92. Geisinger K, Ng LW, Hopkins MB, Barrett RJ, Homesley HD. Tenckhoff catheter cytology in patients with ovarian cancer. *Cancer* 1988; 62:1582-1585.
93. Savarese JJ, Thomas GB, Homesley HD, Hill CS. Rescue factor: a design for evaluating long-acting analgesics. *Clin Pharmacol Ther* 1988; 43:376-380.
94. Sutton GP, Blessing J, Photopoulos G, Berman ML, Homesley HD. Phase II experience with ifosfamide/mesna in gynecologic malignancies: preliminary report of Gynecologic Oncology Group Studies. *Sem Oncol* 1989; 16(1 suppl 3):68-72.
95. Ng LW, Homesley HD, Barrett RJ, Welander C, Case L. CA-125 values predictive of clinical response during second-line chemotherapy for epithelial ovarian cancer. *Am J Clin Oncol* 1989; 12(2):106-109.
96. Walton LA, Blessing JA, Homesley HD. Adverse effects of intraperitoneal fluorouracil in patients with optimal residual ovarian cancer after second-look laparotomy: A Gynecologic Oncology Group Study. *J Clin Oncol* 1989; 7(4):466-470.
97. Thigpen JT, Blessing J, Homesley HD, Creasman WT, Sutton G. Phase II trial of cisplatin as first-line chemotherapy in patients with advanced or recurrent endometrial carcinoma: A Gynecologic Oncology Group study. *Gynecol Oncol* 1989; 33:68-70.
98. Sutton GP, Blessing J, Homesley HD, Berman ML, Malfetano J. Phase II trial of ifosfamide and mesna in advanced ovarian carcinoma: a Gynecologic Oncology Group study. *J Clin Oncol* 1989; 7(11):1672-1676.
99. Homesley HD. Morphine: immediate release vs. controlled release. *NC Med J* 1989; 50(7):390-394.
100. Homesley HD. Cisplatin-based chemotherapy of epithelial ovarian cancer. *J Surg Oncol* 1989; 1:21-25.

101. Williams SD, Blessing J, Moore DH, Homesley HD, Adcock L. Cisplatin, vinblastine, and bleomycin in advanced and recurrent ovarian germ cell tumors. A trial of the Gynecologic Oncology Group. *Ann Internal Med* 1989; 111:22-27.
102. Homesley HD, Scarantino CW, Muss HB, Welanders C. Concurrent chemotherapy and single high dose plus whole abdominopelvic radiation for persistent ovarian carcinoma. *Gynecol Oncol* 1989; 34:170-174.
103. Morrow CP, Bundy B, Homesley HD, Creasman WT, Hornback WB, Kurman R, Thigpen J. Doxorubicin as an adjuvant following surgery and radiation therapy in high risk endometrial carcinoma stage I and occult stage II: A Gynecologic Oncology Group Study. *Gynecol Oncol* 1990; 36(2):166-171.
104. Creasman WT, Gall S, Bundy BN, Beecham J, Mortel R, Homesley HD. Second-look laparotomy in the patient with minimal residual stage III ovarian cancer. *Gynecol Oncol* 1989; 35(3):378-82.
105. Young RC, Walton LA, Ellenberg SS, Homesley HD, Wilbanks G, Decker DG, Miller A, Parker R, Major F. Adjuvant therapy for comprehensively staged early (FIGO stage I & II) epithelial ovarian cancer: long term results from two prospective clinical trials. *NEJM* 1990; 322(15):1021-1027.
106. Welanders DW, Homesley HD, Smiles KA, Peets EA. Intralesional interferon alpha for the treatment of genital warts. *Am J Obstet Gynecol* 1990; 162(2):348-54.
107. Homesley HD, Blessing J, Schlaerth J, Rettenmair M, Major RJ. Rapid escalation of weekly intramuscular methotrexate for nonmetastatic gestational trophoblastic disease: A GOG study. *Gynecol Oncol* 1990; 38:305-308.
108. Sutton GP, Blessing J, Photopulos G, Berman ML, Homesley HD. Early phase II Gynecologic Oncology Group experience with ifosfamide/mesna in gynecologic malignancies. *Cancer Chemo Pharm* 1990; 26:S55-58.
109. Sutton GP, Blessing J, Photopulos G, Berman ML, Homesley HD. GOG experience with ifosfamide. *Seminars in Oncol* 1990; 17(2 Suppl):6-10.
110. Homesley HD, Bundy B, Sedlis A, Yordan E, Berek JJ, Jahshan A, Mortel R. Assessment of current international federation of gynecology and obstetrics staging of vulvar carcinoma relative to prognostic factor for survival (A Gynecologic Oncology Group Study). *Am J Obstet. Gynecol* 1991; 164:997-1004.



111. Morrow CP, Bundy B, Kurman RJ, Creasman W, Heller P, Homesley HD, Graham SE. Relationship between surgical pathological risk factors and outcome in clinical I and II carcinoma of the endometrium: A Gynecologic Oncologic Group study. *Gynecol Oncol* 1991; 40:55-65.
112. Malfetano JH, Blessing J, Homesley HD, Hanjani P. A phase II trial of gallium nitrate in the treatment of patients with advanced or recurrent squamous cell carcinoma of the cervix: A Gynecologic Oncology Group study. *Invest New Drugs* 1991; 9(1):109-111.
113. Welander CE, Homesley HD, Barrett RJ. Combined interferon  $\alpha$  and doxorubicin in the treatment of advanced cervical cancer. *Am J Obstet Gynecol* 1991; 165(2):284-291.
114. Williams SD, Blessing J, Hatch K, Homesley HD. Chemotherapy of advance dysgerminomas: trials of the Gynecologic Oncology Group. *J Clin Oncol* 1991; 8(11):1950-1955.
115. Omura GA, Brady MR, Homesley HD, Yordan E, Major R, Buchsbaum HJ, Park R. Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: the Gynecologic Oncology Group Experience. *J Clin Oncol* 1991; 9(7):1138-50.
116. Thigpen JT, Blessing J, Beecham J, Homesley HD, Yordan E. Phase II trial of cisplatin as first-line chemotherapy in patients with advanced or recurrent uterine sarcomas: a Gynecologic Oncology Group study. *J Clin Oncol* 1991; 9(11):1962-1966.
117. Young DS, Lentz SS, Barrett RJ, Homesley HD, Moore JS Outpatient management of malignant ascites using ultrasound, a trocar, and a Tenckhoff catheter. *Int J Gynecol Cancer*. 1992 Jul; 2(4):175-178.
118. Kadar N, Malfetano, Homesley HD. Determinants of survival of surgically staged patients with endometrial carcinoma histologically confined to the uterus: implications from therapy. *Obstet Gynec* 1992; 80:655-659.
119. Markman M, Berek J, Blessing JA, McGuire WP, Bell J, Homesley HD. Characteristics of patients with small volume residual ovarian cancer unresponsive to cisplatin-based IP chemo- therapy: lessons learned from a gynecologic oncology group phase II trial of IP cisplatin and recombinant alpha-interferon. *Gynecol Oncol* 1992; 45:3-8.
120. Kadar N, Homesley HD, Malfetano J. Positive peritoneal cytology is an adverse factor in endometrial carcinoma only if there is other evidence of extrauterine disease. *Gynecol Oncol* 1992; 46:145-149.

121. Homesley HD, Kadar N, Barrett RJ, Lentz SS. Selective Pelvic and Periaortic Lymphadenectomy does not increase morbidity in surgical staging of endometrial carcinoma. *Amer J Ob Gynecol* 1992; 167:1225-1230.
122. Sutton GP, Blessing JA, Manetta A, Homesley HD, McGuire W. Gynecologic Oncology Group studies with ifosfamide. *Cancer* 1992; 19:31-34.
123. Sugihara K, Collins LA, Homesley HD, Welander C. An in-vitro thymidine incorporation assay for human cancers: technical details revisited. *Inter J Cell Cloning* 1992; 10:334-351.
124. Homesley HD. Revised 1988 International Federation of Gynecology and Obstetrics staging systems for endometrial and vulvar cancer: an assessment. *Clinical Obstetrics & Gynecology*, 35 (1):89-94, 1992 Mar.
125. Homesley HD, Harry DS, O'Toole RV, Hoogstraten B, Franklin E, Cavanagh D, Nahhas W, Smith J. Randomized comparisons of cisplatin plus epirubicin or doxorubicin for advanced epithelial ovarian carcinoma: a multicenter trial. *Amer J Clin Oncol* 1992; 15:129-134.
126. Webster KD, Twiggs L, Homesley HD, Barrett RJ, Blessing JA. Circadian-timed combination doxorubicin-cisplatin chemotherapy for advanced endometrial carcinoma a phase II study of the Gynecologic Oncology group. *Am J Clin Oncol*. 1993; 16(6):494-496.
127. Wentz A, Shemano I, Rebar R, O'Toole R, Mullin T, Lynden C, Lovelace J, Homesley HD, Hickox P, Harry D, Gams R, Bump R. Antiestrogen potency of Toremifen and tamoxifen in postmen-postmenopausal women. *Amer J Clin Oncol* 1993; 16:117-122.
128. Homesley HD, Hahn WF, Melees, Heck K, Barrett R, Lentz SS, Woodlief, Lovelace J. Randomized comparison of antiemetic efficacy of a serotonin type 3 receptor antagonist (MDL72,222) with a multiple drug high dose metaclopramide regimen. *Amer J Clin Oncol* 1993; 16:175-179.
129. Young RC, Long JH, Homesley HD, Brady MR, Averette J. Localized ovarian cancer in the elderly: the Gynecologic Oncology Group Experience. *Cancer* 1993; 71:601-605.
130. Welander CE, Homesley HD, Higashihara J, Collins LA, Berens ME. Combined antiproliferative activity of 5-fluorouracil and mitomycin-C against primary human ovarian tumors and cell lines in a clonogenic assay. *Gynecol Oncol* 1993; 48:171-179.

131. Yordan E, Sedlis A, Mortel R, Jahshan A, Homesley HD, Bundy BN, Berek JS. Prognostic factors related to groin node metastases in squamous cell carcinoma of the vulva. *Gynecol Oncol* 1993; 49(3):279-283.
132. Malfetano JH, Kadar N, Homesley HD. Steroid receptor concentrations in endometrial carcinoma: effect on survival in surgically staged patients. *Gynecol Oncol* 1993; 50(3):281-286.
133. Lentz SS, Homesley HD, Barrett R. Topical sucralfate in the treatment of vaginal ulceration. *Obstet Gynecol* 1993; 81(5):869-871.
134. Look KY, Clarke-Pearson DAN, Homesley HD, Blessing JA, Asbury RF. A Gynecologic Oncology Group phase II study of amonafide in epithelial ovarian cancer. *Am J Clin Oncol Cancer Clin Trials*. 1993; 16(6):529-531.
135. Sutton GP, McGuire WP, Homesley HD, Blessing JA, Adcock L. Phase II Study of ifosfamide- and mesna in refractory adenocarcinoma of the endometrium. A Gynecologic Oncology Group Study. *Cancer*, 73(5):1453-5, 1994 Mar 1.
136. Thigpen T, Stehman FB, Homesley HD. Cancers of the uterine cervix and endometrium: major issues and future research directions. *Seminars in Oncology*, 21(1):114-8, 1994 Feb.
137. McGuire WP, Hoskins WJ, Homesley HD, Creasman WT, Brady MF, Berman M, Berek JS, Ball H. The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patient with suboptimal residual epithelial ovarian carcinoma. *Am J Ob Gyn* 1994; 170(4):974-980.
138. Sutton GP, Malfetano JH, Homesley HD, Blessing JA. A phase II trial of ifosfamide and mesna in patients with advanced or recurrent mixed mesodermal tumors of the ovary previously treated with platinum-based chemotherapy: A Gynecologic Oncology Study Group. *Gyn Onc* 1994 ;( 53):24-26.
139. Malfetano J, Kadar N, Homesley H. Prognostic factors in surgical stage III and IV carcinoma of the endometrium. *Obstet and Gynec.*1994; 84:983-986.
140. Lentz SS, Homesley HD. Radiation-Induced Vesicosacral Fistula: Treatment with Continent Urinary Diversion. *Gynecologic Oncology* 1995; 58, 278-280.
141. Yanovich S, Williams L, Weisbert S, Stuart L, Ritch P, Reich S, Podczaski E, Perez E, Nahhas W, McCarroll K, Karp D, Homesley H, Hoff J, Gandara D, Diasio R, Braly P, Adelson M. Randomized Placebo-Controlled Multicenter Evaluation of Diethyldithiocarbamate for Chemoprotection Against Cisplatin-Induced Toxicities. *Journal of Clinical Oncology*. 1995; 13-490-496

142. Woodward J, McGuire WP, Hoskins WJ, Homesley HD, Brady MF, Creasman WT, Berman ML, Berek JS, Ball H. An assessment of dose intense therapy in suboptimally debulked ovarian cancer: A Gynecologic Oncology Group study. *J Clin Onc.* 1995; 13; 1589-1599.
143. Braly PS, Berek JS, Blessing JA, Homesley HD, Averette H. Intraperitoneal Administration of Cisplatin and 5-Fluorouracil in Residual Ovarian Cancer: A Phase II Gynecologic Oncology Group Trial. 1995(56):164-168.
144. Homesley HD. Management of Vulvar Cancer, *CANCER Supp.*, 1995(76): 2159-2170.
145. McGuire WP, Hoskins WJ, Brady MF, Homesley HD, Creasman WT, Berman ML, Ball H, Berek JS, Woodward J. Assessment of Dose Intense Therapy in Suboptimally Debulked Ovarian Cancer: A Gynecologic Oncology Group Study. *J. Clin. Oncol.* 1995;13: 1589-1599.
146. Malfetano JH, Blessing JA, Homesley HD. A Phase II Trial of gallium nitrate (NSC: 15200) in Nonsquamous Cell Carcinoma of the Cervix. A Gynecologic Oncology Group Study. *Am J Clin Oncol* 1995; 18(6):495-497.
147. Gandara DR, Nahhas WA, Adelson MD, Lichtman SM, Podczaski ES, Yanovich S, Homesley HD, Braly P, Ritch PS, Weisberg SR. Et al. Randomized placebo-controlled multicenter evaluation of diethyldithiocarbamate for chemoprotection against cisplatin-induced toxicities. *J of Clin Onc.* 1995; 13(2):490-6.
148. Randall ME, Barrett RJ, Spirtos NM, Chalas E, Homesley HD, Lentz SL, Hanna M. Chemotherapy, early surgical reassessment, and hyperfractionated abdominal radiotherapy in stage III ovarian cancer: results of a gynecologic oncology group study. *Int J Radiat Oncol Biol Phys.* 1996 Jan 1; 34(1): 139-47.
149. Kemp G, Rose P, Lurain J, Berman M, Manetta A, Rouillet B, Homesley H, Belpomme D, Glick J. Amifostine Pretreatment for Protection Against Cyclophosphamide and Cisplatin-induced Toxicities: Results of a Randomized Control Trial in Patients with Advanced Ovarian Cancer. *J. Clin. Oncol.* 1996; 14: 2101-2112.
150. Kris MG, Cubeddu LX, Gralla RJ, Cupissol D, Tyson LB, Venkatraman E, Homesley HD. Are more antiemetic trials with placebo necessary? Report of patient data from randomized trials of placebo antiemetics with cisplatin. *Cancer.* 1996; 78: 2193-2198.
151. Markman M, Homesley H, Norberts DA, Schink J, Abbas F, Miller A, Soper J, Teng N, Hammond N, Muggia F, Israel M, Sweatman T. Phase I Trial of Intraperitoneal AD-32 in Gynecologic Malignancies. *Gynecol. Oncol.* 1996; 61 (1):90-3.

152. Malfetano JH, Blessing JA, Homesley HD, Look KY, McGehee R. A Phase II Trial of didemnin B (NSC: 335319) in Patients with Advanced Squamous Cell Carcinoma of the Cervix. A Gynecologic Oncology Group Study. *Am J Clin Oncol.* 1996; 19(2):184-6.
153. Reisinger SA, Asbury R, Liao SY, Homesley HD. A Phase I Study of Weekly Cisplatin and Whole Abdominal Radiation for the Treatment of Stage III and IV Endometrial Carcinoma: A Gynecologic Oncology Group Pilot Study. *Gynecol. Oncol.* 1996; 63:299-303.
154. Look KY, Brunetto MA, Clarke-Pearson DL, Averette HE, Major FJ, Alvarez RD, Homesley HD, Zaino RJ. An Analysis of Cell Type in Patients with Surgically Staged Stage IB Carcinoma of the Cervix: A Gynecologic Oncology Group Study. *Gynecol. Oncol.* 1996; 63(3):304-311.
155. Kris MG, Cubeddu LX, Gralla RJ, Cupissol D, Tyson LB, Venkatraman E, Homesley HD. Are More Antiemetic Trials with a Placebo Necessary? Report of Patient Data from Randomized Trials of Placebo Antiemetics with Cisplatin. *Cancer.* 1996; 78(10):2193-8.
156. Kemp G, Rose P, Lurain J, Berman M, Manetta A, Roullet B, Homesley HD, Belpomme Glick Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer. *Journal Clinical Oncology.* 1996; 14(7): 2101-12.
157. Markman M, Homesley HD, Norberts DA, Schink J, Abbas F, Miller A, Soper J, Teng N, Hammond N, Muggia F, Israel M, Sweatman T. Phase I trial of intraperitoneal AD-32 in gynecologic malignancies. *Gynecologic Oncology.* 1996; 61(1):90-3
158. Fleming RA. Capizzi RL. Muss HB. Smith S. Fernandes DJ. Homesley H. Loggie BW. Case L. Morris R. Russell GB. Richards F. Phase I study of N-(phosphonacetyl)-L-aspartate with fluorouracil and with or without dipyridamole in patients with advanced cancer. *Clinical Cancer Research.* 2(7):1107-14, 1996 Jul.
159. Rose PG, Blessing JA, Mayer AR, Homesley HD. Prolonged Oral Etoposide As Second-Line Therapy for Platinum-Resistant and Platinum-Sensitive Ovarian Carcinoma: A Gynecologic Oncology Group Study. *J. Clin Onc.* 1998; 16:405-410.

160. Creasman WT, Zaino RJ, Major FJ, DiSaia PJ, Hatch KD, Homesley HD. Early Invasive Carcinoma of the Cervix (3-5 mm invasion) Risk Factors and Prognosis: A Gynecologic Oncology Group Study. *Amer. J. Obstet. Gynecol* 1998; 178:62-65.
161. Markman M, Lichtmanh SM, Homesley HD, Kennedy A, Webster K, Ernst S, Belinson J. Phase 2 Trial of Moderately High Dose Single Agent Mitoxantrone in Platinum and Paclitaxel-Refractory Ovarian Cancer. *Gynecologic Oncology*. 1998; 70:123-126.
162. Spector Jesse I, Lester Eric P, Chevlen EM, Sciortino D, Harvey JH, Whaley W, Madajewicz S, Isaacs R, Homesley HD, Yee S, Beck T, Tchekmedyian S, Crawford K, Arnes M, Creek MR. A Comparison of Oral Ondansetron and Intravenous Granisetron for the Prevention of Nausea and Emesis Associated with Cisplatin-Based Chemotherapy. *The Oncologist*. 1998; 3:432-438.
163. Muggia FM, Blessing JA, Homesley HD, Sorosky J. Tomudex in Platinum-Pretreated Recurrent Epithelial Ovarian Cancer: A Phase II Study by the Gynecologic Oncology Group. *Cancer Chemotherapy & Pharmacology*. 1998; 42:68-70.
164. Markman M, Lichtman SM, Homesley H, Kennedy A, Webster K, Ernst S, Omura G, Belinson J. Phase 2 trial of moderately high dose single agent mitoxantrone in platinum and paclitaxel-refractory ovarian cancer. *Gynec. Oncol* 1998; 70(1) 123-6.
165. Muggia FM, Blessing JA, Homesley HD, Sorosky J. Tomudex in platinum-pretreated recurrent epithelial ovarian cancer: a phase II study by the Gynecologic Oncology Group. *Cancer Chemo & Pharm*. 1998; 42(1) 68-70.
166. Rose PG, Blessing JA, Mayer AR, Homesley HD. Prolonged oral etoposide as second therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study. *J. of Clin. Oncol*. 1998; 16 (2) 405-10.
167. Muggia FM, Blessing JA, Homesley HD, Sorosky J. Tomudex (ZD1694, NSC639186) in platinum-pretreated recurrent epithelial ovarian cancer: a phase II study by the Gynecologic Oncology Group. *Cancer Chemother Pharmacol*. 1998; 42(1): 68-70.
168. Bundy BN, Hurteau JA, Roth LM. Bleomycin, etoposide, and cisplatin combination therapy of ovarian granulosa cell tumors and other stromal malignancies: A Gynecologic Oncology Group study. *Gyne. Oncol*. 1999; 72(2): 131-7.
169. Burger RA DiSaia PJ, Roberts JA, O'Rourke M, Gershenson DM, Homesley HD, Lichtman SM, Barnes W, Moore DH, Monk BJ. Phase II trial of vinorelbine in

recurrent and progressive epithelial ovarian cancer. *Gynecol Oncol.* 1999; 72(2): 148-53.

170. Thigpen JT, Brady MF, Alvarez RD, Adelson MD, Homesley HD, Manetta A, Soper JT, Given FT. Oral Medroxyprogesterone Acetate in the Treatment of Advanced or Recurrent Endometrial Carcinoma: A Dose-Response Study by the Gynecologic Oncology Group. *J. Clin. Oncol.* 17(6): 1736-44, 1999.
171. Homesley HD, Bundy BN, Hurteau, JA, Roth LM. Bleomycin, etoposide, and cisplatin combination therapy of ovarian granulosa cell tumors and other stromal malignancies: A Gynecologic Oncology Group study. *Gynecol Oncol.* 1999 Feb; 72(2):131-7.
172. Homesley HD, Hall DJ, Martin DA, Lewandowski GS, Vaccarello L, Nahhas WA, Suggs CL, Penley RG A dose-escalating study of weekly bolus topotecan in previously treated ovarian cancer patients. *Gynecol Oncol.* 2001 Nov; 83(2):394-9.
173. Thigpen T, Brady MF, Homesley HD, Soper JT, Bell J. Tamoxifen in the treatment of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. *J Clin Oncol.* 2001 Jan 15; 19(2): 364-7.
174. Homesley H, Benigno B, Williams J, Vaccarello L. A Phase I Study of Weekly Topotecan and Paclitaxel in Previously Treated Ovarian Carcinoma Patients. *Gynecol Oncol.* 2002 Nov; 87 (2): 171-177.
175. Homesley HD, Boike G., Spiegel GW Feasibility of Laparoscopic management of presumed stage I endometrial carcinoma and assessment of accuracy of myoinvasion estimates by frozen section: a gynecologic oncology group study. *Int. Gynecol Cancer* 2004 14, 1-7
176. Tate Thigpen J, Blessing JA, DeGeest K, Look KY, Homesley HD; Gynecologic Oncology Group. Cisplatin as initial chemotherapy in ovarian carcinosarcomas: a Gynecologic Oncology Group study. *Gynecol Oncol.* 2004 May;93(2):336-9.
177. Thigpen JT, Brady MF, Homesley HD, Malfetano J, DuBeshter B, Burger RA, Liao S. Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a gynecologic oncology group study. *J Clin Oncol.* 2004 Oct 1;22(19):3902-8.
178. Sutton G. Axelrod JH. Bundy BN. Roy T. Homesley HD. Malfetano JH. Mychalczak BR. King ME. Whole abdominal radiotherapy in the adjuvant treatment of patients with stage III and IV endometrial cancer: a gynecologic oncology group study. *Gynecologic Oncology.* 97(3):755-63, 2005 Jun.

179. Homesley HD, Blessing JA, Sorosky J, Reid G, Look KY. Phase II trial of liposomal doxorubicin at 40 mg/m<sup>2</sup> every 4 weeks in endometrial carcinoma: a Gynecologic Oncology Group Study. *Gynecologic Oncology*. 98(2):294-8, 2005 Aug.
180. Sutton, G, Axelrod, J Bundy, B N. Roy, T. Homesley, H. Lee, R. B. Gehrig, P. A. Zaino, R. Adjuvant whole abdominal irradiation in clinical stages I and II papillary serous or clear cell carcinoma of the endometrium: a phase II study of the Gynecologic Oncology Group. *Gynecologic Oncology*. 100(2):349-54, 2006 Feb.
181. Moll S, Kenyon P, Bertoli L, De Maio J, Homesley H, Deitcher SR. Phase II Trial of Alfimeprase, a Novel-Acting Fibrin Degradation Agent, for Occluded Central Venous Access Devices JCO Jul 1 2006: 3056-3060.
182. DiSilvestro PA, Walker JL, Morrison A, Rose PG, Homesley HD, Warshal D. Radiation therapy with concomitant paclitaxel and cisplatin chemotherapy in cervical carcinoma limited to the pelvis: A phase I/II study of the Gynecologic Oncology Group. *Gynecol. Oncol., Issue 3, December 2006*, 103: 1038-1042
183. Homesley HD, Filiaci V, Markman M, Bitterman P, Eaton L, Kilgore LC, Monk BJ, Ueland FR. Phase III Trial of Ifosfamide With or Without Paclitaxel in Advanced Uterine Carcinosarcoma: A Gynecologic Oncology Group Study JCO Feb 10 2007: 526-531.
184. Homesley HD, Meltzer NP, Nieves L, Vaccarello L, Lowendowski GS, and Elbendary AA. A phase II trial of weekly one hour paclitaxel as a second-line therapy of endometrial and cervical cancer. *IJCO* Feb. 2008, 13:1: 62-65.
185. Martee L, Hensley ML, John A, Blessing JA, Koen DeGeest K, Ovadia Abulafia O, Peter G, Rose PG, Howard D, Homesley HD. Fixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: A Gynecologic Oncology Group phase II study *Gynecologic Oncology*, 109, Issue 3, June 2008, Pages 323-328
186. Ballard, K, Tedjarati, S, Robinson, W, Homesley, Thurston, E. Embryonal Rhabdomyosarcoma: Adjuvant and Ex Vivo Assay Directed Chemotherapy (*In Press*)



187. Simpkins F, Gibbons H, Tian C, Homesley H, Kunos, C Radiation Therapy versus Pelvic Node Resection for Node Positive Vulvar Cancer: Follow-up of a Gynecologic Oncology Group Study [ Submitted Ob/Gynec]
188. Homesley H, Filiaci V, Gibbons, S, Long H, Cella D, Spirto, N, Morris R, DeGeest K, Lee R, Montag A. A randomized phase III trial in advanced endometrial carcinoma of surgery and volume directed radiation Gynecologic Oncology Group study. Gynecologic Oncology 112 (2009) 543–552. [Selected for Faculty of 1000 Medicine ([www.f1000medicine.com](http://www.f1000medicine.com)) and evaluated by Paola Gehrig see <http://www.f1000medicine.com/article/d0pk6mklrjymcw/id/1158196>. Faculty of 1000 Medicine ([www.f1000medicine.com](http://www.f1000medicine.com)) is a revolutionary literature awareness service that identifies and evaluates the most important articles published in Medicine based on the recommendations of a Faculty of over 2000 peer-nominated leading researchers and clinicians. Your article's identification and inclusion provides recognition from your peers of its scientific merit and the positive contribution it makes to the medical literature ].
189. Kunos C, Simpkins F, Gibbons H, Tian C, Homesley H. Node Resection for Node-Positive Vulvar Cancer: A Randomized Controlled Trial. Ob/Gyn: Vol. 114, No. 3, Sept. 2009.
190. Ballard KS, Tedjarati S, Robinson WR, Homesley HD, Thurston E. Embryonal Rhabdomyosarcoma: Adjuvant and In-Vitro Assay Directed Chemotherapy. Int J Gynecol Cancer. 2010 May; 20 (4): 561-563

## **II.C. ABSTRACTS**

1. Zaritzky D, Resnick MI, Homesley HD, Cunningham JJ, Blake D. Rectal ultrasonography as a diagnostic aid in the staging of carcinoma of the cervix. *Invest Radiol* 1977; 12:406.
2. White Dr, Spurr CL, Richards F, Muss HB, Homesley HD, Cooper MR. Vincristine, cyclophosphamide, and Adriamycin in advanced ovarian cancer. *Proc AACR/ASCO* 1978; 19:415.
3. Thigpen JT, Prem K, Mladineo J, Homesley H. Phase II trial of piperazinedione in treatment of advanced squamous cell carcinoma of the cervix. *Proc AACR/ASCO* 1978; 19:162.
4. Lewis GC, Homesley H, Brady L, Blessing J. Radiotherapy (RT), chemotherapy (CT) and combined therapy in stage III epithelial ovarian cancer. *Proc AACR/ASCO* 1979; 20:388.
5. Thigpen T, Shingleton H, Homesley HD. Phase II trial of Cis-platinum as first or second-line treatment for advanced squamous cell carcinoma of the cervix. *Proc AACR/ASCO* 1979; 20:388.
6. Mladineo J, Mangan C, Homesley H, Ehrlich C, Blom J, Blessing J. Dianhydrogalactitol (DAG) in the treatment of advanced gynecologic malignancies. *Proc AACR/ASCO* 1980; 21:416.
7. Homesley H, Dolan T, DiSaia P, Bundy B, Arseneau JC. Phase II trial of Baker's antifol (NSC 139,105) in advanced cervical carcinoma. *Proc AACR/ASCO* 1980; 21:424.
8. Omura GA, Morrow CP, Homesley HD, Buchsbaum HJ, Blessing J. Follow-up on a randomized trial of melphalan (M) versus melphalan plus hexamethylmelamine (M+H) vs. Adriamycin plus cyclophosphamide (A+C) in advanced ovarian adenocarcinoma. *Proc AACR/ASCO* 1981; 22:470.
9. Slayton R, Prem KA, Homesley H, Blessing J. Adjuvant vincristine, dactinomycin and cyclophosphamide (VAC) chemotherapy in malignant germ cell tumors of the ovary. *Proc AACR/ASCO* 1981; 22:387.
10. Thigpen JT, Muss HB, Jobson VW, Homesley HD. Chemotherapy of advanced carcinoma of the cervix with cyclophosphamide and cisplatin. A pilot study of the Gynecologic Oncology Group. *Proc AACR/ASCO* 1981; 22:475.
11. Marshall RB, Kuchler LK, Homesley HD, Breedin PH. Fallopian tube and pelvic cytology in endometrial carcinoma. *Acta Cytol* 1981; 25:436-437.

12. Welander CE, Spurr C, Jobson VW, Muss HB, Kimball J, Homesley HD, Gainey J. Failure of delta-9-tetrahydrocannabinol and prochlorperazine to control chemotherapy induced nausea and vomiting. Proc ASCO 1982; 1:67.
13. Thigpen T, Shingleton H, Homesley H, Blessing J. Phase II trial of cis-diamminedichloroplatinum (DDP) in treatment of advanced or recurrent mixed mesodermal sarcoma of the uterus. Proc ASCO 1982; 1:110.
14. Welander CE, Homesley HD, Gaines JT. Improved cloning efficiency (CE) in the human tumor stem cell assay (HTSCA) using ficoll gradient cell separation. Proc AACR 1983; 24:311.
15. Welander CE, Parker RL, Jobson VW, Homesley HD. Chemotherapy sensitivity of carcinomas of the cervix (CACX) determined by the human tumor stem cell assay (HTSCA). Proc ASCO 1983; 2:22.
16. Welander CE, Rudnick S, Homesley H, Gaines J. In-vitro synergistic effects of recombinant human interferon alpha<sub>2</sub> (rIFN- $\alpha_2$ ) and doxorubicin on human tumor cell lines. Proc ASCO 1983; 2:42.
17. Young RC, Walton L, Major F, Homesley H, Ellenberg S, Decker S. Early stage ovarian cancer: preliminary results of randomized trials after comprehensive initial staging. Proc ASCO 1983; 2:148.
18. Welander C, Tran LL, Spurr C, Pippitt C, Muss HB, Jobson VW, Jackson D, Homesley H. Treatment of recurrent gynecologic malignancies with prolonged intravenous vincristine (VCR) infusion. Proc ASCO 1983; 2:149.
19. Scarantino C, Muss H, Homesley H. Concurrent single high dose irradiation (SHDI) and cisplatin (CP) or hexamethylmelamine (HMM) in drug resistant advanced ovarian carcinoma. Proc ASCO 1983; 2:150.
20. Welander CE, Jobson VW, Homesley HD. Comparison of heparin and intermittent calf compression for prevention of pulmonary embolism. Gynecol Oncol 1983; 15:143. Williams S, Homesley H, Blessing J, Adcock L. Treatment of ovarian germ cell tumors with cisplatin + vinblastine + bleomycin (PVB). Proc ASCO 1984; 3:175.
21. Wells B, Welander C, Muss HB, Jobson V, Homesley H, Ferree C, Cisplatin chemotherapy (CT) followed by radiotherapy (RT) in patients with advanced cervical carcinoma. Proc ASCO 1984; 3:170.
22. Zekan P, White D, Stuart J, Spurr C, Richards F, Powell B, Poole M, Paschold G, Muss H, Jobson V, Jackson D, Hopkins J, Homesley H, Craig J, Cooper M, Capizzi R, Atkins J. A phase I study of high dose ara-C (HiDAC) in patients with solid tumors. Proc ASCO 1984; 3:42.

23. Welander CE, Spiegel RJ, Muss HB, Homesley HD. Phase I-II trial of sequential human interferon alpha<sub>2</sub> (rIFN $\alpha$ <sub>2</sub>) and doxorubicin (DOX) in advanced malignancies. Proc ASCO 1984; 3:64.
24. Whisnant J, Homesley HD, Creasman W, DiSaia P, Abdulhay G. Human lymphoblastoid interferon (HlyIFN) in the treatment of advanced epithelial ovarian malignancies: a Gynecologic Oncology Group study. Proc ASCO 1984; 3:167.
25. Slavik M, Petty WM, Homesley HD, Creasman WT, Blessing JA. Phase II clinical study of tamoxifen (TMX) in advanced or recurrent endometrial carcinoma. Proc ASCO 1984; 3:171.
26. Welander CE, Kuteh WH, Harbourne KS, Homesley HD, Doellgast GJ. Characterization of autologous antibodies isolated from the membrane fragments of human ovarian neoplasms. Fed Proc 1984; 43:1621.
27. Sedlis A, Marshall R, Homesley H, Bundy B. Positive groin lymph nodes in vulvar cancer with superficial tumor penetration. Gynecol Oncol 1984; 17:259-
28. Wilbanks G, Morrow CP, Homesley HD, Creasman WT, Bundy B. Recurrence in endometrial carcinoma as a function of extended surgical staging data. Am Radium Soc #2 1984; 7:114?
29. Wilbanks G, Morrow CP, Homesley HD, Creasman WT, Bundy B. Recurrence in endometrial carcinoma as a function of extended surgical staging data. Gynecol Oncol 1984; 17:262-263. Williams S, Slayton R, Homesley HD, Blessing J. Treatment of ovarian germ cell tumors with cisplatin + vinblastine + bleomycin: long-term results of therapy. Gynecol Oncol 1984; 17:262.
30. Marshall RB, Kute TE, Geisinger KR, Homesley HD. Endometrial adenocarcinoma: a multimodality analysis. Lab Invest 1985; 52:24A.
31. Welander CE, Jones CM, Homesley HD, Berens ME. In-vitro growth and chemosensitivity of endometrial cancer. Proc ASCO 1985; 4:113.
32. Sutton GP, Slayton RE, Park R, Homesley HD, Blessing JA. A phase II clinical trial of diaziquone (AZQ) in advanced ovarian cancer. Proc ASCO 1985; 4:118.
33. Welander CE, Spiegel RJ, Muss HB, Homesley HD. Phase II trial of combined human interferon alpha<sub>2</sub> (rIFN $\alpha$ <sub>2</sub>) and doxorubicin (DOX) in advanced solid tumors. Proc ASCO 1985; 4:220.
34. Welander CE, Homesley HD. Dosing range study of MS Contin in patients with chronic cancer pain. Proc ASCO 1985; 4:272.

35. Welander C, Reich S, Levin E, Homesley H. Phase II trial of the efficacy of human recombinant interferon gamma (rIFN $\gamma$ ) in recurrent ovarian adenocarcinomas. *Proc ASCO* 1986; 5:221.
36. Welander CE, Ng LW, Geisinger KR, Hopkins MB III, Homesley HD, Barrett R. Tenckhoff catheter cytology in ovarian cancer. *Acta Cytol* 1987; 31:649.
37. Welander CE, Homesley HD, Berens M, Barrett R. Serum CA-125 levels and the human tumor clonogenic assay (HCTA) as pathologic and prognostic discriminators of borderline ovarian tumors. *Proc ASCO* 1987; 6:6.
38. Welander C, Homesley H, Grossberg H, Geisinger K, Barrett R. Peritoneal cytology as a means of response evaluation for intraperitoneal therapy of minimal residual ovarian cancer. *Proc ASCO* 1988; 7:141.
39. Smith M, Peters W, LaGasse L, Homesley H, Fu Y, Berek J, Barrett R. Primary malignant mixed Mullerian tumor (MMT) of the cervix. *Proc ASCO* 1988; 7:144.42. Welander C, Ng L, Geisinger K, Hopkins M, Homesley H, Barrett R. Tenckhoff catheter cytology in patients with ovarian cancer. *Proc ASCO* 1988; 7:144.
40. Williams S, Slayton R, Photopulos G, Homesley H, Blessing J. Ovarian germ cell tumors: adjuvant trials of the Gynecologic Oncology Group. *Proc ASCO* 1989; 8:150.
41. Omura GA, Miller A, Major F, Homesley HD, Gordon E, Buchsbaum H, Brady MF. Long follow-up and prognostic factor analysis in very advanced (large volume) ovarian carcinoma: The Gynecologic Oncology Group Experience. *Proc ASCO* 1989; 8:151.
42. Schlaerth JB, Rettenmeir MA, Major FJ, Homesley HD, Blessing JA. Dose intensity study of weekly intramuscular methotrexate for nonmetastatic gestational trophoblastic disease. A Gynecologic Oncology Group Study. *Proc ASCO* 1989; 8:156.
43. Welander CE, Perez J, Homesley HD, Cantrell J, Barrett R. Phase I trial of intraperitoneal ovamid in patients with residual advanced ovarian cancer. *Proc ASCO* 1989; 8:160.
44. Yordan E, Sedlis A, Mortel R, Jahshan M, Homesley HD, Bundy BN, Berek JS. Clinical and surgicopathologic findings in squamous cell carcinoma of the vulva: A Gynecologic Oncology Group study. 2<sup>nd</sup> Meeting of the International Gynecologic Cancer Society Proceedings 1989:60.

45. Smith J, O'Toole R, Nahhas W, Franklin E, Hoogstraten B, Homesley HD, Harry D, Cavanaugh D. Randomized comparison of cisplatin plus epirubicin or doxorubicin for advanced ovarian cancer. A Multicenter Trial Proc ASCO 1990; 9:162.
46. Williams SD, Homesley HD, Hatch K, Blessing J. Chemotherapy of advanced ovarian dysgerminoma: Trials of the Gynecologic Oncology Group (GOG) Proc ASCO 1990; 9:155.
47. White D, Smith S, Rhinehardt D, Richards R, Muss H, Lovelace L, Homesley H, Fernandes D, Cruz J, Cooper MR, Case D, Capizzi R, Barrett R, Barbery R. Randomized phase II and clinical pharmacologic trial of PALA/5-FU  $\pm$  dipyridamole in patients with advanced cancer. Proc ASCO 1992; 11:123
48. Taplin M, Schnipper L, Muss H, Huhn R, Homesley H, Eder J, Come S. Repeated intensive cyclophosphamide, doxorubicin and VP-16 with recombinant human granulocyte-macrophage colony stimulating factor (rhGM-CSF). Proc ASCO 1992; 11:404.
49. McGuire WP, Hoskins WJ, Homesley HD, Clarke-Pearson D, Copeland L, Brady MS. Serum CA-125 for prediction of progression in advanced epithelial ovarian carcinoma. Proc ASCO 1992; 11:223.
50. McGuire WP, Hoskins WJ, Homesley HD, Clarke-Pearson D, Brady M. A phase III trial of dose intense versus standard dose cisplatin and Cytosin in advanced ovarian cancer. Proc ASCO 1992; 11:226.
51. Woodlief L, McLees B, Lovelace JV, Lentz SS, Homesley HD, Heck K, Hahne WF, Barrett RJ. Randomized comparison of antiemetic efficacy of a serotonin type 3 receptor antagonist (MDL 72,222) with a multiple drug high dose metoclopramide regimen. PROC ASCO 1992; 11:398.
52. Yordan E, Thigpen T, Malfetano J, Homesley H, DiSaia P, Blessing J. Phase III trial of doxorubicin +/- cisplatin in advanced or recurrent endometrial carcinoma: A Gynecologic Oncology Group (GOG) study. Proc ASCO 1993; 12:261.
53. Malta E, Malfetano J, Homesley HD, Dziem G, Brown J, Braly P, Benigno B, Bean L, Abrams J. Filgrastin (r-met-HuG-CSF) as an adjunct to cyclophosphamide and carboplatin chemotherapy in advanced ovarian carcinoma. Proc ASCO 1993; 12:265.
54. Randall ME, Spirtos N, Lentz SL, Homesley HD, Chalas E, Barrett RJ. Chemotherapy, early surgical reassessment and hyperfractionated abdominal RT in stage III ovarian cancer: preliminary results of a Gynecologic Oncology Group trial. Int J Gynecologic cancer 1993; 3 :( 1):68.

55. Homesley HD. High risk endometrial cancer workshop. *Int J Gynecol Cancer* 1993; 3:1.
56. Wideman GL, Karrow S, Kanton TG, Homesley HD, Hall NR, Doyle RT, Baird W. Repeat dose comparison of ibuprofen hydrocodone vs. acetaminophen and codeine combinations. *Am Soc Clinical Pharmacology Therapeutics* 1993; 53(2):173.
57. Sundberg DF, Sterchi JM, Rogers AT, Loggie BW, Lentz S, Kashtan H, Homesley HD, Frazier J, Charles D, Barrett R. Intraperitoneal hyperthermic chemotherapy for advanced gastrointestinal and ovarian cancers. *SSO* 1993; 3:126.
58. Sweatman TW, Payne C, Norbergs A, Muggia F, Miller B, Miller A, Markman M, Israel M, Homesley HD. Clinical pharmacology of intraperitoneal (IP) N-trifluoroacetyladiamycin-14-valerate (AD 32). *AACR* April 1994; 35:245.
59. Klockowski JM, Homesley HD. A Randomized, double-blind, placebo-controlled, multicenter, study recombinant interferon-beta (rebif) administered by the intralesional route in the treatment of condyloma acuminatum in men and women. 1995
60. Thigpen T, Sutton G, Lincoln S, Homesley H, Blessing J. Phase II Trial of Cisplatin in Mixed Mesodermal Sarcomas of the Ovary. 1995
61. Ball H, Blessing J, Lentz S, Mutch D. A Phase II Trial of Taxol in Advanced and Recurrent Adenocarcinoma of the Endometrium: A Gynecologic Oncology Group Study. *Gynecol. Oncol.* 1995; 56: 120.
62. Rose PG, Blessing JA, Mayer AR, and Homesley HD. Prolonged Oral Etoposide as Second-Line Therapy for Platinum Resistant and Platinum Sensitive Ovarian Carcinoma: A Gynecologic Oncology Group Study. *Proc. ASCO*; 15, 282, 1996.
63. Thigpen T, Blessing J, Homesley H, Reid G, Olt G. Cisplatin as Salvage Therapy in Ovarian Carcinoma Treated Initially with Single-Agent Paclitaxel: A Gynecologic Oncology Group Study. *Proc. ASCO*; 15, 287, 1996.
64. Muggia F, Blessing J, Homesley H, and Sorosky J. Tomudex: Minimal Activity in Previously Treated Epithelial Ovarian Cancer. *Proc. ASCO*; 15, 301, 1996.
65. Homesley H, Hall D, Martin D, Suggs C, Lewandowski G. Phase I/II Trial of Escalating Doses of Weekly Topotecan as a Second or Third Line Regimen for Epithelial Ovarian Cancer. *Proc ASCO*; 18, 376a, 1999.

66. Homesley H, Hall D, Martin G, Lewandowski G, Vaccarello L, Nahhas W. Weekly Bolus Topotecan Toxicity and Dose Response Trial in Second or Third Line Therapy of Epithelial Ovarian Carcinoma. Proc. ASCO, 19, 395a, 2000.
67. Homesley H, Blessing J, Sorosky J, Reid G, Look K. Liposomal Doxorubicin Every Four Weeks in Endometrial Carcinoma, A Gynecologic Oncology Study, Proc. ASCO, 2005
68. Homesley H, Vaccarello L, Lowendowski G, Elbendary, A. A phase II trial of weekly one hour paclitaxel as second-line therapy for endometrial and cervical cancer. Proceedings of ASCO, 15013: 651s, 2006.
69. Radiation Therapy versus Pelvic Node Resection for Carcinoma of the Vulva with Positive Groin Nodes: An Update of a Gynecologic Oncology Group Study. Simpkins F, Heidi Gibbons, Tian, C, Kunos C, Homesley H. Gynecol. Oncol. 2008: S2.
70. Homesley HD, Filiaci V, Gibbons SK, Long JH, Spirtos NM, Morris RT, et al. Randomized phase III trial in advanced endometrial carcinoma of surgery and volume-directed radiation followed by cisplatin and doxorubicin with or without paclitaxel: a Gynecologic Oncology Group Study. Gynecol. Oncol 2008: 108: S2.
71. Chen, L, Homesley, H. D., Scribner, DR Jr, Cantuaria, G., He, Q, Cheek, RL, Whitehead, CM, Doobay, H, Fischer, TJ, Performance of a biomarker panel to identify malignancy within a pelvic mass population. ASCO 2009



**IID. NON-PEER REVIEW ARTICLES:**

1. Homesley HD. Evaluation of the abnormal Pap smear. Am Fam Physician 1977; 16:190-194.
2. Homesley HD. Annual report on the results of treatment in gynecological cancer. Kottmeir, Hans-Lidvig, Editor. International Federation of Gynecology and Obstetrics, Publisher. No. 17, 1979.
3. Homesley HD, Fowler WC, Creasman WT. Screening for cervical cancer: 1982 - an update. NC Med J 1982; 43:771-773.
4. Homesley HD. Staging, surgical debulking, and second-look laparotomy. Adv Oncol 1985; 1:15, 18-19.
5. Welander CE, Jobson VW, Homesley HD. Annual report on the results of treatment in gynecologic cancer. Kottmeir HV, Editor, International Federation of Gynecology and Obstetrics, Publisher, 1982:18.
6. Welander CE, Homesley HD, Barrett RJ. Annual report on the results of treatment in gynecological cancer. Petersson F, editor, International Federation of Gynecology and Obstetrics, Publisher, 1985:19.
7. Wells HD, Welander CE, Muss HB, Jobson VW, Homesley HD, Gainey JM. Cisplatin chemotherapy and emesis in patients given metoclopramide. New Engl J Med 1982; 307:250. (Letter)
8. Kessinger A, Homesley HD, Conroy JF, Blessing JA. Phase II trial of razoxane in the management of recurrent adenocarcinoma of the ovary: a Gynecologic Oncology Group study. Cancer Treat Rep 1984; 68:439-440. (Short communication)
9. Homesley HD. Gynecologic Oncology, Knapp RC, Berkowitz RS, editors. New Engl J Med 1986; 315:592. (Book Review)
10. Savarese JJ, Homesley HD, George E. Analgesia with controlled-release morphine tablets in breast and gynecological cancer. ACOG (Poster), 1987.
11. Welander CE, Ng LW, Homesley HD, Case D, Barrett RJ. Predictive value of CA-125 in second-line therapy of epithelial ovarian carcinoma. International Gynecologic Cancer Society (Poster), 1987.
12. Homesley HD. Staging and current treatment for endometrial cancer. Oncology 1987; 1:53-57.

13. Homesley HD. Assessment of colposcopic skills. *Colposcopy Gynecol Laser Surg* 1987; 3:135-138.
14. Sedlis A, Marshall R, Homesley HD, Bundy BN. Evaluating risk factors for vulvar cancer. *Contemp Ob/Gyn* 1988;40:67-74.
15. Homesley HD, Cohen CJ, Buchsbaum HJ. Vulvar carcinoma. *ACOG Audio Update*, 1989; 14(9).
16. Sutton GP, Photopulos G, Homesley HD, Berman ML, Blessing JA. Phase II experience with ifosfamide/mesna in gynecologic malignancies: preliminary report of Gynecologic Oncology Group studies. *Seminars in Oncology* 1989; 16(1 Suppl 3):68-72.
17. Homesley HD. Cisplatin-based chemotherapy of epithelial ovarian cancer. *Jour Surg Onc Supplement* 1989; 1:21-25.
18. Homesley HD. Vulvar malignancy: Therapeutic consequences for patients with metastatic involvement of inguinal lymph nodes. *Proceedings of the 12<sup>th</sup> World Congress of Gynecology and Obstetrics*, 1989.
19. Homesley HD. Practical gynecologic surgery: principles in practice, Mark E. Boyd. *New Engl J Med* 1990; 322:1475-1476. (Book Review)
20. Homesley HD. "Commentary for Vulvar Cancer by Neville F. Hacker." *J Oncol* 1990; 4:33.
21. Lentz S, Kadar N, Homesley H, Barrett R. Poster: Selective Pelvic/Para-aortic Lymphadenectomy Does Not Increase Morbidity and Surgical Staging of Endometrial Carcinoma. *The International Gynecologic Cancer Society*, Cairns, Australia, September 23, 1991.
22. Homesley HD. Development of Single-Agent Chemotherapy Regimens for Gestational Trophoblastic Disease. *Journal of Reproductive Medicine* 1994; 39(3): 185-192.
23. Homesley HD. Cancer Consultations, Breast Cancer, "When, if ever, is it reasonable to use hormone replacement therapy in women who have had breast cancer?" *Primary Care & Cancer* 1992; 12(9):22.
24. Homesley HD. Cancer Consultations, Ovarian Cancer, "The Cost of CA-125 and Vaginal Ultrasound," *Primary Care & Cancer*, 1993; 13(7):15.
25. Homesley HD, Zaino R. Prognostic factors. In: Homesley HD, ed. *Seminars in Oncology*. 1994; 21:71-78.

26. Homesley HD, Zaino R. "Endometrial Cancer: Prognostic Factors," Seminars in Oncology, 1994; 21(1):71-78.
27. Homesley HD. "Carcinoma of the Endometrium: Issues of the 1990s," Seminars in Oncology 1994; 21(1):63.
28. Homesley HD. "Safety of hormone replacement in women who have had breast cancer," Cancer Consultations; Editors, Abeloff MD and Wittes RE. A PRR Publication, Huntington, NY 1:68-69, 1994
29. Homesley HD. Lymph node findings and outcome in squamous cell carcinoma of the vulva, @ Cancer, 1994; 84(6):983-986.
30. Homesley HD, Muss HB. Role of Chemotherapy Dose Intensification in the Treatment of Advanced Ovarian Cancer. @ Review. ONCOLOGY. 1995; 9; 992.
31. Homesley HD. "Clinical Opinion: Management of Endometrial Cancer." Amer. J. of Obstet. Gynec. 1995;174; 529-534.
32. Homesley HD. Management of Vulvar Cancer. Cancer. 1995; 76(10 Suppl):2159-70.
33. Homesley HD. Management of Endometrial Cancer. American Journal of Obstet Gynecol. 1996;174(2):529-34.
34. Homesley HD. Single Agent Therapy of Nonmetastatic and Low Risk Gestational Trophoblastic Disease. Editors: Berkowitz RS, Goldstein DP. Symposium on Gestational Trophoblastic Disease. J. of Reprod. Med. 1998; 43:69-74.
35. Homesley, HD Tip of the Month, Women and Cancer Magazine, September, 2008.
36. Homesley, HD, Present status and future direction of clinical trials in advanced endometrial carcinoma, J Gynecol. Oncol., 19, No. 3 157-161, 2008.

**III. PRESENTATIONS:**

1. "Menstrual Dysfunction Following Use of Oral Contraceptives." American College of Obstetrics and Gynecology Junior Fellows, New Orleans, Louisiana, (Second Prize Award), June 1969.
2. "Is There a 'Best Time' for a Postpartum Vaginal Hysterectomy?" American College of Obstetrics and Gynecology Junior Fellows Meeting, Nashville, Tennessee, (Second Prize Award), October, 1971.
3. "Treatment of Adenocarcinoma of the Endometrium at Memorial-James Ewing Hospitals." American College of Obstetrics and Gynecology Annual Meeting, Miami, Florida, May, 1973.
4. "Stage II Endometrial Adenocarcinoma - Memorial Hospital for Cancer." North Carolina Obstetrics-Gynecology Society, Sea Island, Georgia, October, 1974.
5. "Treatment of Endometrial Adenocarcinoma at Memorial Hospital New York 1884-1976. Endometrial Carcinoma and Its Treatment." American Cancer Society Symposium, Louisville, Kentucky, November, 1975.
6. "Management of Gynecologic Disorders." North Carolina Academy of Family Practice Annual Meeting, Winston-Salem, North Carolina, November, 1975.
7. "Dysplasia Clinic." Frank R. Lock Symposium, Winston-Salem, North Carolina, March, 1976.
8. "Carbon Dioxide Cystoscopy." Southern Ob/Gyn Seminar, Asheville, North Carolina, July, 1976.
9. "How Should I Manage an Adnexal Mass?" Postgraduate Course of the Medical College of Virginia, Richmond, Virginia, December, 1976.
10. "Evaluation of Urinary Incontinence." Southern Gynecologic and Obstetrical Society, Dallas, Texas, November, 1977.
11. "Reassessment of the Treatment of Carcinoma of the Cervix, Stage IV." Felix Rutledge Society, Washington, D.C., June, 1978.
12. "Therapeutic and Prognostic Significance of Lesion Size in stage IB Carcinoma of the Cervix." Soc. of Memorial Gyn. Oncologists, New York, N Y, November, 1978.
13. "Gynecologic Oncology and Antibiotic Therapy." Medical College of Georgia Lecture, May 31, 1980.

July 1, 2010

14. "Pieces of Paper and a Model Society." Presidential Address, Society of Memorial Gynecologic Oncologists, Bethesda, Maryland, October 24, 1980.
15. "Chemotherapy of Advanced Epithelial Carcinoma with Melphalan and Levamisole." Study of the Gynecologic-Oncology Group, Society of Memorial Gynecologic Oncologists, Bethesda, Maryland, October 25, 1980.
16. "Use of Carbon Dioxide Laser in Therapy of Lesions of the Vulva, Vagina, and Cervix." Society of Memorial Gynecologic Oncologists, Bethesda, Maryland, October 25, 1980.
17. "Role of Bulk Reduction in Improving Survival of Patients with Advanced Ovarian Cancer." Society of Memorial Gynecologic Oncologists, Bethesda, Maryland, October 25, 1980.
18. "Management of Endometrial Carcinoma." University of California at Irvine Postgraduate Course, Incline Village, Nevada, January 22, 1981.
19. "Cervical Lesion Size Related to Survival in Stage I Cervical Carcinoma." Society of Memorial Gynecologic Oncologists, Haiti, November 18, 1981.
20. "Use of Four-Quadrant Biopsies in Colposcopic Training." South Atlantic Association of Obstetrics and Gynecology, New Orleans, Louisiana, February 2, 1982.
21. "Current Patterns of Care in Cervical Intraepithelial Neoplasia." Society of Memorial Gynecologic Oncologists, Montreal, Canada, September 11, 1982.
22. "Laser Therapy in Gynecology." University of Illinois, Chicago, Illinois, October 4, 1982.
23. "Laser Therapy in Gynecology." Symposium on Treatment of Cancer of the Cervix and Ovary. Institute of Obstetrics and Gynecology, University of London, Queen Charlottes Maternity Hospital, London, England, December 1, 1982.
24. "The Case for Surgical Staging in Cervical Cancer." Symposium on Treatment of Cancer of the Cervix and Ovary. Institute of Obstetrics and Gynecology, University of London, Queen Charlottes Maternity Hospital, London, England, December 1, 1982.
25. "In-Vitro Chemotherapy Sensitivity Testing of Gynecologic Tumors." Symposium on Treatment of Cancer of the Cervix and Ovary. Institute of Obstetrics and Gynecology, University of London, Queen Charlotte's Maternity Hospital, London, England, December 1, 1982.
26. "Sub-specialization in the USA." Symposium on Treatment of Cancer of the

Cervix and Ovary. Institute of Obstetrics and Gynecology, University of London, Queen Charlotte's Maternity Hospital, London, England, December 2, 1982.

27. "Pitfalls of Colposcopy." Memphis Obstetrics/Gynecologic Society, Memphis, Tennessee, February 28, 1983.
28. "Current Management of Ovarian Cancer." Baptist East Hospital Conference, Memphis, Tennessee, February 28, 1983.
29. "Control of Chemotherapy Induced Nausea and Vomiting." Grand Rounds, Baptist Medical Center, Jackson, Mississippi, March 23, 1983.
30. "Intraperitoneal Chemotherapy in Ovarian Carcinoma." Grand Rounds, University of Mississippi Medical Center, Jackson, Mississippi, March 25, 1983.
31. "The Value of Four Quadrant Biopsies in Teaching Residents Colposcopy." Felix Rutledge Society Meeting, Houston, Texas, June 3, 1983.
32. "Is There Life After Vulvectomy?" Society of Gynecologic Nurse Oncologists. Denver, Colorado, July 20, 1983.
33. "Leukemogenesis Related to Chemotherapy for Ovarian Carcinoma." Society of Memorial Gynecologic Oncologists Sixth Annual Meeting, Dublin, Ireland, September 19, 1983.
34. "Radical Surgery for Carcinoma of the Vulva." Symposium on Carcinoma of the Vulva, Vagina, Corpus Uteri and on Late Stage Gynecological Malignancy. Institute of Obstetrics and Gynecology, University of London, London, England, September 26, 1983.
35. "Methods of Training Colposcopy to Obstetrical and Gynecology Residents." Presented as a participant in the China-United States Scientific Exchange, Wuxi, China, and October 26, 1983.
36. "The Assessment of Colposcopic Skills by Residents." Combined Meeting of the American Society of Colposcopy and Cervical Pathology and the Gynecologic Laser Society. Lake Buena Vista, Florida, March 12, 1984.
37. "Intraperitoneal Chemotherapy in Advanced Ovarian Cancer." Eighth Annual Symposium of Gynecologic Oncology and Surgery. Vanderbilt University Medical Center, Nashville, Tennessee, April 27, 1984.
38. "Evaluation of Colposcopic Competence." Eighth Annual Symposium of Gynecologic Oncology and Surgery, Vanderbilt University Medical Center, Nashville, Tennessee, April 27, 1984.

July 1, 2010

39. "Evaluation of Colposcopic Skills." Grand Rounds, Department of Obstetrics, Eastern Virginia Medical School, Norfolk, Virginia, August 23, 1984.
40. "Dosing Range Study of Morphine Sulfate Continus Tablets in Patients with Chronic Pain." Society of Memorial Gynecologic Oncologists, St. Louis, Missouri, October 13, 1984.
41. "Randomized Study of Radiation Therapy Versus Pelvic Node Resection for Patients with Invasive Squamous Cell Carcinoma of the Vulva Having Positive Groin Nodes." Society of Gynecologic Oncologists, Miami, Florida, February 4, 1985.
42. "Gynecologic Oncology Group Cervical and Vulvar Studies." North Carolina Ob/Gyn Society Meeting, Southern Pines, North Carolina, May 4, 1985.

**Presentations 43-57 were made November 17 - December 2, 1985 while in Japan as a Visiting Professor at Kyushu University, Fukuoka, Japan.**

43. "Cancer Research and the Role of Gynecologic Oncology Group." Presented to Kyushu Faculty of Medicine, Department of Ob/Gyn, Kyushu University, and Fukuoka, Japan.
44. "In-Vitro Chemotherapy Sensitivity Testing of Gynecologic Tumors." Presented to Kyushu Faculty of Medicine, Dept of Ob/Gyn, Kyushu Univ., and Fukuoka, Japan.
45. "Treatment of Advanced Ovarian Carcinoma." Presented to Kyushu Faculty of Medicine, Department of Ob/Gyn, Kyushu University, and Fukuoka, Japan.
46. "New Development in Research and Treatment for Gynecologic cancer." Presented to Kyushu University, Ob/Gyn Alumni, Fukuoka, Japan.
47. "Carcinoma of the Vulva." Presented to Kyushu Faculty of Medicine, Department of Ob/Gyn, Kyushu University, and Fukuoka, Japan.
48. "Treatment of Advanced and Recurrent Carcinoma of the Cervix." Presented to Kyushu Faculty of Medicine, Department of Ob/Gyn, Kyushu University, and Fukuoka, Japan.
49. "Treatment of Endometrial Adenocarcinoma." Presented Okayama University School of Medicine, Okayama, Japan.
50. "Adenocarcinoma of the Endometrium." Presented to Kyushu Faculty of Medicine, Kyushu University, and Fukuoka, Japan.
51. "Current Gynecologic Oncology Studies." Presented to Fukuoka University

School of Medicine, Fukuoka, Japan.

52. "Complications of Cancer Chemotherapy." Presented to Luncheon Conference, Kyushu University Hospital, and Kyushu, Japan.
53. "Control of Pain in the Cancer Patient." Presented to Luncheon Conference, Kyushu University Hospital, and Kyushu, Japan.
54. "Gynecologic Urology." Presented to Luncheon Conference, Kyushu University Hospital, and Kyushu, Japan.
55. "Interesting Phase I-II Studies of New Chemotherapeutic Agents in GOG." Presented to Gynecologic Oncology Rounds, Kyushu University, Kyushu, Japan.
56. "Use of Cisplatin in Gynecologic Cancer." Presented at Gynecologic Oncology Rounds, Kyushu University, Kyushu, Japan.
57. "Adenocarcinoma of the Endometrium and Current GOG Studies." Presented at Kitasato University, Tokyo, Japan.
58. "Colposcopic Learning Techniques." American Society for Colposcopy and Cervical Pathology Annual Meeting, Boston, Massachusetts, April 15, 1986.
59. "Radiotherapy for Positive Groin Nodes - The GOG Experience." Fourth International Conference on Gynecologic Cancer, San Francisco, California, May 1, 1986.
60. "Cancer Pain Management." Miami Cancer Society, Miami, Florida, January 30, 1987.
61. "Single Agent Weekly Methotrexate for Low Risk Gestational Trophoblastic Disease." Society of Gynecologic Oncology, Miami, Florida, February 4, 1987.
62. "Vulvar Carcinoma Update." Gynecologic Oncology Update, University of Minnesota, Minneapolis, Minnesota, May 19, 1987.
63. "Vulvar Condyloma" and "Carcinoma of the Vulva." Yale University, New Haven, Connecticut, September 17, 1987.
64. "Management of Positive Groin Nodes in Vulvar Carcinoma." International Gynecologic Cancer Society, Amsterdam, Holland, October 6, 1987.
65. "Germ Cell Tumors of the Ovary." Northwest Community Hospital, Chicago, Illinois, November 14, 1987.
66. "Pain Management in the Gynecologic Oncology Patient." Christiana Hospital,



67. "Ovarian Carcinoma." Cleveland Memorial Hospital, Shelby, North Carolina, March 15, 1988.
68. "Obstetric and Gynecologic Forum Moderator." Lake Buena Vista, Florida, May 28, 1988.
69. "Treatment of Ovarian Cancer." XXVI World Congress of the International College of Surgeons, Milan, Italy, July 4, 1988.
70. Panel Discussion of Vulvar Carcinoma - Audio Digest for the American College of Obstetricians and Gynecologists, New York, New York, September 26, 1988.
71. "Surgical Aspects of Ovarian Cancer," Piedmont Oncology Association, Baltimore, Maryland, September 30, 1988.
72. "Prognostic Significance of Positive Inguinal Nodes in Vulvar Cancer." XII World Congress of the Federation of Obstetrics and Gynecology, Rio de Janeiro, October 25, 1988.
73. "Ovarian Cancer Update." Charlotte Memorial Hospital, Charlotte, North Carolina, November 10, 1988.
74. "Gynecologic Oncology and Pain Management." University of Tennessee at Knoxville Medical Center, Knoxville, Tennessee, November 11, 1988.
75. "Pre-Invasive Lesions of Vulva." Seminar in Gynecology, Virginia Beach, Virginia, February 6, 1989.
76. "Operations for Ovarian Cancer." Portsmouth General Hospital, Portsmouth, Virginia, February 8, 1989.
77. "Prognostic Factors in Vulvar Cancer." Ohio State University Medical Center, Columbus, Ohio, March 23, 1989.
78. "Use of Analgesics in Oncology Patients." Doctors' Hospital, Columbus, Ohio, March 23, 1989.
79. "Current Therapy of Ovarian Cancer." Womack Army Hospital, Fayetteville, North Carolina, April 4, 1989.
80. Seminar on "Chemotherapy on Gynecologic Malignancies." Mercy Hospital, Charlotte, North Carolina, April 14, 1989.
81. "New Approaches to Ovarian Cancer." Mercy Hospital, Charlotte, North

Carolina, April 14, 1989.

82. "Epithelial Ovarian Neoplasm." Alamance Hospital, Burlington, North Carolina, May 10, 1989.
83. "Current and Future Directions in Management of Ovarian Carcinoma." The Annual Lemuel Bowden Symposium of Gynecologic Cancer, Central New York Academy of Medicine, Utica, New York, June 15, 1989.
84. "All You Need to Know About Ovarian Carcinoma." Spartanburg Regional Hospital Staff, Spartanburg, South Carolina, September 11, 1989.
85. "Hazards in Diagnosis of Lesions of the Vulva." Milton S. Hershey Medical Center, Grand Rounds, Hershey, Pennsylvania, October 4, 1989.
86. "Survival Factors in Ovarian Cancer." Poly Clinic, Grand Rounds, Harrisburg, Pennsylvania, October 4, 1989.
87. "Cancer Pain Management." Cancer Center Grand Rounds, West Virginia Medical Center, Charleston, West Virginia, January 29, 1990.
88. "Colposcopy Update." Piedmont Obstetrical and Gynecology Society, Hickory, North Carolina, July 17, 1990.
89. "Trends in Treatment of Endometrial Carcinoma." Society of Memorial Gynecology Oncology, Malmo, Sweden, September 29, 1990.
90. "Pain Management in the 90's." Clayton County Hospital, Riverdale, Georgia, December 7, 1990.
91. "Vulvar Cancer." Medical College of Virginia, Richmond, Virginia, January 17, 1991.
92. "Endometrial Carcinoma in the 90's." West Virginia ACOG Section, Huntington, West Virginia, March 16, 1991.
93. "Ovarian Cancer-The GOG Experience." Nashville OB Gyn Society, Nashville, Tennessee, March 22, 1991.
94. "Conservative Management of Vulvar Cancer." Vanderbilt University Medical Center, Nashville, Tennessee, March 23, 1991.
95. "Clinicopathologic Prognostic Factors in Vulvar Cancer." American College of Obstetrics and Gynecology, New Orleans, Louisiana, May 8, 1991.
96. Presidential Panel on FIGO Staging: Proposed Staging for Vulvar Carcinoma

July 1, 2010

- Based on Risk Group Analysis of the Independent Prognostic Factors for Survival (A Gynecologic Oncology Group study). International Gynecologic Cancer Society, Cairns, Australia, September 25, 1991.
97. Selective Pelvic and Para-aortic Lymph Node Sampling in Endometrial Carcinoma Does Not Increase Morbidity. The Society of Memorial Gynecologic Oncologists, Philadelphia, Pennsylvania, September 11, 1991.
  98. Panel on Gynecologic Oncology: Endometrial Carcinoma: Preoperative Evaluation, Surgical Staging, Lymph Node Sampling. American College of Surgeons, October 22, 1991.
  99. GOG Clinical Trials. Faculty of Medicine of Kyushu University, Fukuoka, Japan, March 1992.
  100. Clinical Trial of Epirubicin in Ovarian Cancer. Western Japan Gynecologic Oncology Society. Fukuoka, Japan, March 1992.
  101. Loop Conization. Kyushu University, Department of Obstetrics and Gynecology, March 1992.
  102. Look Before You LEEP. North Carolina Obstetrical and Gynecological Society, Williamsburg, Virginia, April 4, 1992.
  103. Harold A. Schwartz Lectureship. Chattanooga University of the College of Medicine, December 5, 1992.
  104. Gynecologic Oncology Colony Stimulating Factors. Grand Rounds, Department of Obstetrics and Gynecology. Birmingham, Alabama, April 7, 1993.
  105. Discussant Davis and Geck. ACOG Film Festival for Staging for Ovarian Cancer by ORR J., MD, May 31, 1993.
  106. Moderator and Participant: The GOG Experience in Vulvar Cancer Word Congress for Cervical Pathology and Colposcopy, Chicago, Illinois, May 14, 1993.
  107. High Risk Endometrial Carcinoma. Florida Gynecologic Oncologists Meeting, June 5, 1993.
  108. Prediction of lymph node metastasis in vulvar cancer. Gynecologic Oncology Symposium, Hacettepe University Faculty of Medicine, Ankara, Turkey, October 8, 1993.
  109. Current management of vulvar cancer in 1993. Gynecologic Oncology Symposium, Hacettepe University Faculty of Medicine, Ankara, Turkey, October

8, 1993.

110. What is the Gynecologic Oncology Group? Gynecologic Oncology Symposium, Hacettepe University Faculty of Medicine, Ankara, Turkey, October 8, 1993.
111. High Risk Endometrial Carcinoma. Fourth Biennial Meeting of the International Gynecologic Cancer Society, Stockholm, Sweden, August 29-September 2, 1993.
112. Management of Early Vulvar Cancer.” Twelfth Annual Gynecological Surgery Seminar, Baptist Memorial Hospital, Memphis, Tennessee, November 20, 1993.
113. Loop Pitfalls. Twelfth Annual Gynecological Surgery Seminar, Baptist Memorial Hospital, Memphis, Tennessee, November 20, 1993.
114. Microinvasive Carcinoma of the Vulva. Denis Cavanaugh Symposium, University of South Florida, Orlando, Florida, February 11, 1994.
115. Trends in Management of Endometrial Cancer. Grand Rounds, University of South Florida, Tampa, Florida, March 16, 1994.
116. Stage Ia Carcinoma of the Vulva. MD Anderson, Houston, Texas, March 25, 1994.
117. “Treatment of Low Risk Gestational Trophoblastic Disease.” Fourth Postgraduate Refresher Course in Obstetrics and Gynecology, Singapore, July 11-15, 1994.
118. “Trends in Management of Endometrial Carcinoma.” Fourth Postgraduate Refresher Course in Obstetrics and Gynecology, Singapore, July 11-15, 1994.
119. “Early Vulvar Carcinoma.” Fourth Postgraduate Refresher Course in Obstetrics and Gynecology, Singapore, July 11-15, 1994.
120. An Overview of Cervical Carcinoma.” Fourth Postgraduate refresher Course in Obstetrics and Gynecology, Singapore, July 11-15, 1994.
121. “Ovarian Cancer Update.” Fourth Postgraduate Refresher Course in Obstetrics and Gynecology, Singapore, July 11-15, 1994.
122. “Adenocarcinoma of the Cervix.” Community Hospital, Boca Raton, November 12, 1994.
123. “Management of Vulvar Cancer.” American Cancer Society National Conference on Gynecologic Cancer, Washington, D.C., April 8, 1995.
124. “Prognostic Factors in Vulvar Carcinoma.” Grand Rounds, Henry Ford Hospital,

Detroit, MI., April 13, 1995

125. "Hormonal Treatment Should Be First Line Treatment for Endometrial Carcinoma, July 20, 1995, Controversies in Management of Carcinoma of the Endometrium, Gynecologic Oncology Group Symposium, Charleston, S.C.
126. Discussions "Puget's Disease of the Vulva: DNA ploidy, surgical margins, and recurrent disease." Society of Pelvic Surgery, Lexington, KY, October 14, 1995.
127. "Assessment of Postoperative Fever." Society of Memorial Gynecologic Oncologists, Lake Mohan, N.Y., October 27, 1995.
128. Surgical Staging for Endometrial Cancer: Where & Why Is It Necessary. 19<sup>th</sup> Annual Mid-Winter Symposium, Advances in Obstetrics and Gynecology, Scottsdale, Arizona, March 7-9, 1996.
129. Futuristic Projections in the Treatment of Endometrial Cancer. 19<sup>th</sup> Annual Mid-Winter Symposium, Advances in Obstetrics and Gynecology, Scottsdale, Arizona, March 7-9, 1996.
130. Economic Impact of the Newer Outpatient Regimens for Gestational Trophoblastic Disease. 1996 Society of Gynecologic Oncologists Winter Conference, March 24, 1996, Snowbird, Utah.
131. Advances in the Treatment of Vulvar Carcinoma. Gynecologic Oncology Symposium 1996, Alexia Brothers Medical Center, Elk Grove Village, Illinois, April 13, 1996.
132. "Preinvasive and Invasive Vulvar Carcinoma, All Michigan Ob/Gyn Review Course, Ypsilanti, Michigan, May 24, 1996.
133. "Preinvasive and Invasive Endometrial Carcinoma All Michigan Ob/Gyn Review Course, Ypsilanti, Michigan, May 24, 1996.
134. Cytoprotection, Grand Rounds, Riverside Hospital, Newport News, Virginia, October 17, 1996
135. Endometrial Carcinoma: Current Approaches, Grand Rounds, Robert Wood Johnson School of Medicine and Dentistry, Camden, New Jersey, November 12, 1996.
136. Bleomycin, Etoposide, and Cisplatin Chemotherapy for Granulosa Cell Tumor of the Ovary, Society of Gynecologic Oncologist Annual Meeting, Orlando, Florida, February 10, 1998.
137. Osteoporosis and Hormone Replacement Therapy, Forsyth Medical Center,

Winston-Salem, North Carolina, October 6, 1998.

138. Carcinoma of the Ovary--1998” and Cytoprotection with Amifostene, Dartmouth School of Medicine, Lebanon, New Hampshire, October 29, 1998.
139. Gynecologic Cancer and Cytoprotection, University Hospitals of Cleveland MacDonald Women=s Hospital, Cleveland, Ohio, March 10, 1999.
140. Vulvar Lesions Vanderbilt Grand Rounds, Nashville, Tennessee, October 20, 1999.
141. Avascular Pelvic Spaces, Baptist Hospital Postgraduate Course, Nashville, Tennessee, January 29, 2000.
142. Approaches to Endometrial Carcinoma, Baptist Hospital Postgraduate Course, Nashville, Tennessee, January 29, 2000.
143. “Preinvasive and Invasive Vulvar Carcinoma”, Gyn Oncology Seminar Northwest Community Hospital, Chicago, Illinois, November 11, 2000.
144. “Weekly Topotecan” Audiotape, New York, New York, July 13, 2002.
145. “Dose Finding Study of Weekly Topotecan and Weekly Paclitaxel for Advanced Ovarian Cancer, Society of Memorial Gynecologic Oncology, New York, New York, September 19, 2002.
146. “Monoclonal Antibody Trials in Ovarian Cancer”, Seccion de Ginecologia Oncologica of i.e. Sociedad Espanola de Ginecologia Y Obstetricia, Valladolid, Spain, October 9, 2002.
147. “Vulvar lesions and Vulvar Cancer”, 33<sup>rd</sup> Annual Autumn Seminar in Obstetrics and Gynecology, University of Minnesota, Minneapolis, Minnesota, October 28, 2002.
148. “Incorporating Clinical Trials into Your Busy Practice”, 34<sup>th</sup> Annual Meeting of the Society of Gynecologic Oncology, New Orleans, LA, January 31, 2003.
149. “Conducting Clinical Trials—Pros and Cons”, 35<sup>th</sup> Annual Meeting of the Society of Gynecologic Oncology, San Diego, CA February 11, 2004.
150. “Hormonal Management of Disseminated Endometrial Carcinoma”, International Symposium on Gyn Malignancies, New York, New York, April 17, 2004.
151. “Evaluation and Treatment of Abnormal Pap Smears and HPV Infections”, New Perspectives in Gynecologic Oncology, Alexian Brothers Medical Center, Chicago, Illinois, October 2, 2004.

152. "Update on GOG Protocols." New Perspectives in Gynecologic Oncology, Alexian Brothers Medical Center, Chicago, Illinois, October 2, 2004.
153. "Advances in Treatment of Disseminated Endometrial Cancer." Meet the Experts, Society of Gyn Oncologists, Miami, FL March 19, 2005.
154. Discussant Vulvar Carcinoma Presentations at the Society of Gyn Oncologists, Palm Springs, CA, March 26, 2006.
155. "Phase III Trial of Ifosfamide with or without Paclitaxel in Advanced Uterine Sarcoma: A Gynecologic Oncology Group Study", Society of Gynecologic Oncologist, March 26, 2006
156. "Endometrial Carcinoma Update", Western Japan Gynecologic Oncology Group, Fukuoka, Japan, June 22, 2006.
157. "Current Approaches in Ovarian Cancer", Gynecologic Oncology Symposium, Tokyo, Japan, June 25, 2006.
158. "Chemotherapy of Carcinosarcoma of the Uterus—GOG 161", Gynecologic Oncology Group Semi-Annual Meeting, July 20, 2006.
159. "Phase III Trial of Ifosfamide With or Without Paclitaxel in Advanced Uterine Carcinosarcoma: A Gynecologic Oncology Group Study, Society of Gynecologic Oncology Annual Meeting, Palm Springs, CA, March, 2006.
160. "Treatment for Low and Intermediate Gestational Trophoblastic Disease: What's best?", Society of Gynecologic Oncology Winter Meeting, Park City, UT, February 16, 2008, Park City, UT
161. "A Randomized Phase III Trial in Advanced Endometrial Carcinoma of Surgery and Volume Directed Radiation Followed by Cisplatin and Doxorubicin with or without Paclitaxel: A Gynecologic Oncology Group Study", Society of Gynecologic Oncology Annual Meeting, Tampa, FL, March 9, 2008.

162. " Radiation Therapy versus Pelvic Node Resection for Carcinoma of the Vulva with Positive Groin Nodes: An Update of a Gynecologic Oncology Group Study, Society of Gynecologic Oncology Annual Meeting, Tampa, FL, March 9, 2008.